A genome-wide screen for essential genes that controls the formation of human heart progenitors by Xu, Jiejia
From Department of Cell and Molecular Biology 
Karolinska Institutet, Stockholm, Sweden 
A GENOME-WIDE SCREEN FOR 
ESSENTIAL GENES THAT CONTROLS 
THE FORMATION OF HUMAN HEART 
PROGENITORS 
Jiejia Xu 
 
Stockholm 2018 
 
 All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by AJ E-print AB 
© Jiejia Xu, 2018 
ISBN 978-91-7831-234-4 
A Genome-Wide Screen For Essential Genes That 
Controls The Formation Of Human Heart Progenitors 
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Jiejia Xu 
Principal Supervisor: 
Professor Kenneth Chien 
Karolinska Institutet 
Department of Cell and Molecular Biology 
Department of Medicine 
 
Co-supervisor(s): 
Professor Urban Lendahl 
Karolinska Institutet 
Department of Cell and Molecular Biology 
 
Assistant Professor Xiaojun Lian 
The Pennsylvania State University 
Department of Biomedical Engineering 
Department of Biology 
The Huck Institutes of the Life Sciences 
 
Opponent: 
Professor Mark Mercola 
Stanford University 
Department of Medicine 
Cardiovascular Institute 
  
Examination Board: 
Associate Professor Anna Falk 
Karolinska Institutet 
Department of Neuroscience 
 
Professor Thomas Eschenhagen 
University Medical Center Hamburg-Eppendorf 
Department of Experimental Pharmacology and 
Toxicology 
 
Associate Professor Lars Jakobsson 
Karolinska Institutet 
Department of Medical Biochemistry and 
Biophysics 
 
 
 

  
ABSTRACT 
The heart is a complex organ system composed of multiple types of tissues. These tissues 
are produced by a diverse set of muscle and non-muscle cells, originated from a few pools of 
progenitors. During the heart development, these progenitors are able to expand and 
differentiate in a tightly controlled manner, generating diversified heart cell lineages. The 
progenies from these progenitors interact with each other and ultimately integrate into distinct 
heart tissues. The foundation of a healthy and functional heart stems from the state of its 
progenitor pools. Any errors that occurred during the formation, proliferation, differentiation, 
and assembly of these progenitors are the potential causes of many congenital heart diseases. 
To investigate the cellular mechanisms of human heart development and their implications in 
congenital heart diseases, we face many challenges, two of them are: 1) generation of 
progenitor cells that can self-assemble into mature cardiac tissue that faithfully resembles 
native mature adult cardiac tissue; 2) identification of regulators that controls the formation, 
proliferation and differentiation of these progenitors.  
In paper I, we reported the large-scale generation of an enriched pool of human	pluripotent	stem	cells	(hPSCs)	derived human ventricular progenitors (HVPs). These HVPs 
can build a function ventricular heart muscle in vivo via a cell autonomous pathway, 
including controlled proliferation followed by normal growth, maturation, and self-assembly. 
This tissue generation process of HVPs recapitulates one of the earliest and most essential 
steps of organogenesis. With these properties, HVPs highly likely resembles the progenitors 
that contribute to the ventricular cardiac muscle tissue during human cardiogenesis. In the 
study, we also explore the therapeutic potential of HVPs in heart failure. As a resource for 
further analyzing the genetic and molecular pathways of HVPs, we	also	documented	 the	transcriptomic	 transitions	of	 the	progenitor	 formation	and	subsequent	differentiation	via	sequential	RNA-Seq.	
With the success of generating HVPs, we next try to identify regulators, specifically, the 
ones that control the formation of HVPs.  In paper II, we used CRIPSR-Cas9 system to 
target β-catenin (encoded by CTNNB1), a central component of the canonical WNT signaling 
pathway. The WNT signaling is a major player in cardiogenesis. By temporal modulating the 
WNT/β-catenin signaling pathway with small molecules, high differentiation efficiency 
(>90%) can be achieved. With CTNNB1 mutated hPSCs, we found that Wnt/β-catenin 
signaling is neither required for hPSC self-renewal, nor for neuroectoderm formation. 
However, Wnt/β-catenin signaling is absolutely essential for mesendoderm lineage, including 
cardiac progenitors and cardiomyocytes. This study pinpoints the β-catenin as the master 
switch of the human cardiogenesis.  
Another set of important signaling pathways in cardiogenesis are the TGFβ superfamily 
signaling pathways. Due to the complicate interaction between WNT/β-catenin and the TGFβ 
superfamily signaling pathways, it is difficult to define the roles of TGFβ superfamily 
signaling pathways from chemical inhibition studies. In paper III, we used CRIPSR-Cas9 
system to target SMAD4, a central component in the whole superfamily.  With SMAD4 
mutated hPSCs, we confirmed the dispensable role of SMAD4 for hPSC self-renewal in vitro. 
Furthermore, we demonstrated the essential requirement of SMAD4 in the formation of 
human cardiac mesodermal precursor cell. By transcriptome analysis, we identified that 
SMAD4 mutants failed to differentiate into cardiac mesoderm and, after 6 days, switched to 
neuroectoderm. Primitive steak (PS) genes were expressed in both the wild type and the 
mutant cells on day 1. And interestingly, on day 1, the only active ligand in the TGFβ 
superfamily signaling pathways is NODAL, which specifies the pathway in the family as 
NODAL/SMAD4 pathway. Together, these data suggest that during human mesoderm 
induction, the WNT/β-catenin is responsible for triggering the expression of PS genes, while 
NODAL/SMAD4 is responsible for the feedback enhancement for PS gene expression. This 
study highlights the essential roles of NODAL/SMAD4 signaling pathway in human cardiac 
mesodermal induction. 
In order to unbiasedly uncover the regulators that control the formation of HVPs, in 
paper IV, we developed a genome-wide CRISPR screen based on cardiac differentiation 
from hPSCs. From	 the	 screen	output,	we	 compiled	 a	 list	 of	 15	 candidate	 genes.	After	validating	 7	 of	 these,	 we	 identified	 ZIC2	 as	 an	 essential	 gene	 for	 cardiac	 progenitor	formation.	 ZIC2	 is	 known	 as	 a	 master	 regulator	 of	 neurogenesis.	 hPSCs	 with	 ZIC2	mutated	still	express	pluripotency	markers.	However,	their	ability	to	differentiate	into	cardiomyocytes	 has	 greatly	 reduced.	 Transcriptome profiling	 reveals	 that	 they	 have	switched	to	an	alternative	mesodermal	cell	fate.	Our	results	provide	a	new	link	between	
ZIC2	 and	 human	 cardiogenesis	 and	 document	 the	 potential	 power	 of	 genome-wide	unbiased	CRISPR	screens	 to	 identify	key	 steps	 in	heart	progenitor	 fate	determination	during	human	cardiogenesis	with	hPSC	model	systems. 
In summary, we have generated HVPs, which can self-assemble into human ventricular 
muscle tissue and further identified CTNNB1, SMAD4, and ZIC2 as the essential regulators 
that controlled the formation of HVPs.  
 
  
  
LIST OF SCIENTIFIC PAPERS 
1. Kylie S. Foo+, Miia L. Lehtinen+, Chuen Yan Leung+, Xiaojun Lian, Jiejia Xu, 
Wendy Keung, Lin Geng, Terje RS. Kolstad, Sebastian Thams, Andy On-tik Wong, 
Nicodemus Wong, Kristine Bylund, Chikai Zhou, Xiaobing He, Shao-Bo Jin, 
Jonathan Clarke, Urban Lendahl, Ronald A. Li, William E. Louch, Kenneth R. Chien* 
(2018). Human ISL1+ Ventricular Progenitors Self-Assemble into an In Vivo 
Functional Heart Patch and Preserve Cardiac Function after Infarction. 
Molecular Therapy 6, 1644-1659 
 
2. Xiaojun Lian*, Jiejia Xu, Xiaoping Bao, Lauren N. Randolph (2016). Interrogating 
Canonical Wnt Signaling Pathway in Human Pluripotent Stem Cell Fate Decisions 
Using CRISPR-Cas9.  
Cellular and Molecular Bioengineering  9, 325-334. 
 
3. Jiejia Xu, Peter J. Gruber, Kenneth R. Chien* (2018). SMAD4 Is Essential For 
Human Cardiac Mesodermal Precursor Cell Formation 
[manuscript | Stem Cells, accepted] 
 
4. Jiejia Xu, Chikai Zhou, Kylie S. Foo, Ran Yang, Yao Xiao, Kristine Bylund, 
Kenneth R. Chien* (2018). Genome-Wide CRISPR Screen Identifies ZIC2 As An 
Essential Gene That Controls The Fate of Mesodermal Precursors To Human Heart 
Progenitors. 
[manuscript] 
 
Publications not included in this thesis: 
1. Boon-Seng Soh, Shi-Yan Ng, Hao Wu, Kristina Buac, Joo-Hye C. Park, Xiaojun 
Lian, Jiejia Xu, Kylie S. Foo, Ulrika Felldin, Xiaobing He, Massimo Nichane, Henry 
Yang, Lei Bu, Ronald A. Li, Bing Lim, Kenneth R. Chien* (2016). Endothelin-1 
Supports Clonal Derivation And Expansion Of Cardiovascular Progenitors Derived 
From Human Embryonic Stem Cells. 
Nature Communication 7: 10774. 
 
2. Xiaojun Lian, Jiejia Xu, Jinsong Li, Kenneth R. Chien* (2014). Next-Generation 
Models of Human Cardiogenesis via Genome Editing. (Review) 
Cold Spring Harbor Perspectives in Medicine 4:a013920 
+ These authors contributed equally 
* Correspondent author 
 

  
CONTENTS 
1 Introduction .................................................................................................................... 1 
2 Congenital Heart Disease ............................................................................................... 3 
2.1 Syndromic Congenital Heart Disease .................................................................. 4 
2.2 Non-syndromic Congenital Heart Disease .......................................................... 4 
2.3 Others mechanism ................................................................................................ 6 
3 Cardiogenesis in Murine ................................................................................................ 7 
3.1 Heart development with cardiac progenitors ....................................................... 7 
3.2 The gene language of heart development ............................................................ 8 
3.3 Markers and Lineages ........................................................................................ 11 
3.4 Differences between mice and humans ............................................................. 13 
4 Cardiomyocyte From hPSC ......................................................................................... 15 
4.1 Cardiomyocyte Differentiation .......................................................................... 15 
4.2 Cardiomyocyte Maturation ................................................................................ 17 
4.3 Cardiomyocyte Subtypes ................................................................................... 18 
4.4 Disease Modeling with human PSC-CMs ......................................................... 19 
4.5 Transplantations ................................................................................................. 20 
5 Genomic Technology ................................................................................................... 23 
5.1 Massive Parallel Sequencing .............................................................................. 23 
5.2 Transgenic tools for hPSC ................................................................................. 24 
5.3 Genome Editing in hPSC ................................................................................... 25 
5.4 CRISPR Screen .................................................................................................. 27 
6 Aims ............................................................................................................................. 29 
7 Result Summary ........................................................................................................... 31 
7.1 Paper I: HVP ...................................................................................................... 31 
7.2 Paper II: β-catenin .............................................................................................. 33 
7.3 Paper III: SMAD4 .............................................................................................. 34 
7.4 Paper IV: Screen-ZIC2 ....................................................................................... 36 
8 Discussion .................................................................................................................... 39 
8.1 The Unique Engraftment Property of HVP ....................................................... 39 
8.2 A Peek into The Molecular Complexity of Cardiogenesis ................................ 40 
9 Conclusion .................................................................................................................... 43 
Acknowledgements ............................................................................................................. 45 
References ........................................................................................................................... 47 
 
  
LIST OF ABBREVIATIONS 
hESC human embryonic stem cell 
hiPSC human induce pluripotent stem cell 
hPSC human pluripotent stem cell, hESC or hiPSC 
HVP human ventricular progenitor 
CM cardiomyocyte 
hPSC-CM hPSC derived cardiomyocyte 
NSG next generation sequencing 
MI moycardiac infaction 
GiWi GSK3 inhibition and Wnt inhibition, a cardiomyocyte differentiation protocol 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats  
PS primitive streak 
NuRD Nucleosome Remodeling and Deacetylase 
DSB double strand break 
NHEJ Non-Homologous End Joining  
ZFN  Zinc-finger nuclearase 
TALE Transcription activator-like effector  
HDR Homology Directed Repair 
ORF Open Reading Frame  
PAM protospacer adjacent motif  
sgRNA single chimeric guide RNA 
RNAi RNA interference 
CHD Congenital heart disease 
SHF Second heart field 
FHF First heart field 
SAN Sinoatrial node 
 
 
 
  1 
1 INTRODUCTION 
The heart is the very first organ to form during embryogenesis. This complex organ 
composes of a highly diverse set of cells. Understanding the molecular mechanisms that 
govern the formation, migration, proliferation, differentiation and assembly of these cells into 
different tissues of the heart is the central question in heart development. Since laboratory 
mice rarely have heart problems, the genetic clues usually first came from the congenital 
heart disease patients. About 1% of the live births carry heart defects, which can affect any 
part of the heart. By studying congenital heart diseases (CHDs), critical genes have been 
identified for heart development.  
Once a CHD gene is identified, the mice model becomes very useful. By using 
transgenic mice model, the mechanism of the CHD gene can be explored in depth. Besides 
the loss-of-function approach, genetic lineage analysis can be performed in mice model. 
Lineage is one of the fundamental concepts in development, tracing the origins, namely 
progenitor pools, of every cells in a given heart tissue. Any genetic mutations occurred in 
these progenitor pools might cause defects in the progenitor function and further result in 
structural or functional defects in the heart. Insights from studying mice cardiogenesis have 
brought us from the phenotype-genotype association study to the age of cardiac progenitor 
biology. 
Despite of the prosperity of the transgenic mice model, the complexity of a human heart 
verses a mouse heart is not at the same scale. The mice model study might not truly reflect 
the human conditions. Advances in genome editing in human pluripotent stem cell (hPSC) 
and cardiac differentiation make it possible to use hPSC to model the congenital heart disease 
and study the human cardiogenesis via genome editing. Compared to the mice model, hPSC 
models have one obvious advantage: they have the human genome. 
Here, we will first review and organize the knowledge of heart development from 
disease model, mice model and hPSC model. In addition, we also go over some genomic 
technologies used in our studies. Then, we summarized the present investigations included in 
this thesis. 
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2 CONGENITAL HEART DISEASE 
Heart development requires a complex interplay of the cells in an embryo, including 
migration, proliferation, differentiation, and assembly. Any perturbation in these programs 
can cause defects in heart development or congenital heart disease (CHD). CHD is the most 
common human congenital defect, and the leading cause of death in infants. Worldwide, 1.35 
million infants are born with CHD each year (van der Linde et al. 2011). CHD is also 
identified in 10% of stillbirths (Fahed et al. 2013). Different countries and continents have 
different prevalence of CHD. In North America, the prevalence is 6.9 per 1000 live births; in 
Europe, the incidence is 8.2 per 1,000 live births; in Asia, the prevalence is 9.3 per 1000 live 
births; in Africa, the incidence is 1.9 per 1,000 live births (van der Linde et al. 2011). 
CHD arises during cardiogenesis, manifest itself with various structural and functional 
defects in the heart. CHD affects most parts of the heart, including valves, septa, inflow 
tracts, and outflow tracts. Here are some common heart defects: aortic regurgitation (AR), 
aortic stenosis (AS), atrial septal defect (ASD), atrioventricular septal defect (AVSD), 
bicuspid aortic valve (BAV), coarctation of the aorta (CoA), double outlet right ventricle 
(DORV), hypoplastic left heart syndrome (HLHS), hypoplastic right heart syndrome 
(HRHS), interrupted aortic arch (IAA), mitral regurgitation (MR), mitral valve prolapse 
(MVP), pulmonary atresia (PA), patent ductus arteriosus (PDA), pulmonary stenosis (PS), 
single ventricle (SV), tricuspid atresia (TA), total anomalous pulmonary venous return 
(TAPVR), partial anomalous pulmonary venous return (PAPVR), transposition of great 
arteries (TGA), tetralogy of Fallot (TOF), ventricular septal defect (VSD). Three broad 
categories are used to classified CHDs: cyanotic heart disease, left-sided obstruction defects 
and septation defects (Bruneau 2008). Other types of congenital defects, such as BAV and 
PDA, do not fit neatly into the three main categories. 
The causes of CHD can be genetic or/and environmental. The majority of CHD is 
thought to be associated with gene mutations. However, it turned out to be much more 
complicated to understand the molecular mechanism how these gene mutations cause CHD. 
The complicated picture begins with that not all CHD manifests Mendelian inheritance. 
Secondly, it is difficult to explain with genetic factors that discordant clinical phenotypes 
exist within the same family. From the environmental factors aspect, non-genetic causes of 
CHD include environmental teratogens, maternal exposures, and infectious agents (Fahed et 
al. 2013).  
Simple genotype-phenotype correlations are hard to establish in CHDs. Take familial 
CHD for example. The same single gene mutation can cause different cardiac defects, even 
within the same family. On the other hand, different types of structural malformations can be 
associated with similar gene mutations. CHD arises from the abnormal heart development 
during embryogenesis, a good knowledge of the genetic and cellular mechanism of heart 
development is important for explaining the causes of CHDs. 
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2.1 SYNDROMIC CONGENITAL HEART DISEASE 
Cardiac malformations are the most common malformations in congenital syndromes. 
Congenital heart disease is a primary manifestation is some congenital syndromes. CHD 
occurs in approximately 40% to 50% in Down Syndrome (Antonarakis et al. 2004), 20% to 
50% in Turner syndrome (Phillip et al. 2009), and in almost all in trisomy 18 and 13 (Pont et 
al. 2006). 
DiGeorge Syndrome (DGS) is inherited in an autosomal dominant fashion, but the 
overwhelming majority of deletions occur de novo (Emanuel 2008). The common cause of 
DGS is a 1.5 to 3.0-Mb deletion on chromosome 22q11 (Scambler 2000), which results in 
haploinsufficiency of TBX1 (Jerome and Papaioannou 2001) and other genes. The most 
common diseases are outflow tract anomalies, which include TOF, TOF with PA, truncus 
arteriosus, and IAA (Momma 2010).  
Holt-Oram Syndrome (HOS) manifests as congenital heart disease and upper limb 
dysplasia. HOS is an autosomal dominant disease and caused by mutations in TBX5 gene 
(Basson et al. 1997; Li et al. 1997b). 85% of HOS patients have congenital heart 
malformations (Basson et al. 1994), including secundum ASD, VSD, PDA, and conduction 
system abnormalities. 
Alagille Syndrome is inherited in an autosomal dominant fashion and is commonly 
caused by mutations in JAG1 gene (Li et al. 1997a; Oda et al. 1997). More than 90% of 
individuals with a JAG1 mutation or Alagille Syndrome have cardiovascular anomalies, with 
branch PA stenosis the most common abnormality and other common defects include TOF, 
PS and ASD (McElhinney et al. 2002). 
Noonan Syndrome (NS) is a relatively common multiple congenital anomaly syndrome, 
inherited mostly in an autosomal dominant fashion, with some cases occurring sporadically. 
The affected individuals have characteristic facial features, pterygium colli, short stature, and 
congenital heart abnormality (Noonan 1994). Congenital Heart Disease is found in about half 
of Noonan Syndrome patients, with pulmonary stenosis and hypertrophic cardiomyopathy 
(HCM) are the two most common cardiac manifestations (Noonan 1994; Marino et al. 1999). 
Other symptoms include ASD, TOF, aortic coarctation, mitral valve anomalies and AVC 
(Marino et al. 1999). At least 8 genes were found to be associated with NS, including 
PTPN11, SOS1, RAF1, KRAS, BRAF, MEK1, MEK2, and HRAS (Tidyman and Rauen 2009). 
All the genes are part of the Ras/Raf/MEK/ERK signaling pathway, which involves cell 
proliferation, differentiation, and survival. 
2.2 NON-SYNDROMIC CONGENITAL HEART DISEASE 
Non-syndromic congenital heart disease is the most prevalent form of CHD. The most 
common group of genes implicated in CHD are the transcription factor genes. Other genes, 
such as components signaling transduction pathways, structural components of 
cardiomyocytes, are also common CHD genes. 
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GATA4 mutations are a well-established cause of CHD in humans. The most common 
phenotypes were ASD, VSD, TOF, and AVSD (Garg et al. 2003; Nemer et al. 2006). 
Heterozygous GATA6 mutations usually cause CHD characteristic of a severe form of cardiac 
outflow tract (OFT) defect, namely persistent truncus arteriosus (PTA). (Kodo et al. 2009), 
and sometimes cause ASD and TOF (Lin et al. 2010). 
Many different heterozygous NKX2-5 mutations have been found in patients with CHDs, 
and they were transmitted in an autosomal dominant fashion. (Kasahara et al. 2000). The 
most common phenotype is ASD with or without Atrioventricular (AV) block and other 
common phenotypes are VSD, TOF (Reamon-Buettner and Borlak 2010). 
Apart from Holt-Oram Syndrome, mutations in TBX5 has not been implicated in non-
syndromic CHD, and apart from a single report, findings of mutations in DiGeorge Syndrome 
gene TBX1 have not been duplicated in non-syndromic CHD patients (Fahed and Nemer 
2012). Mutations in TBX20 are associated with a family history of CHD and display a 
complex spectrum of developmental anomalies, including defects in septation, chamber 
growth, and valvulogenesis. (Kirk et al. 2007; Posch et al. 2010). 
As the advances of genomic technology, more and more transcription factors have been 
found to associated with CHDs. X-linked ZIC3 mutations have been identified in cohorts and 
families of cardiac situs abnormalities and TGA (Gebbia et al. 1997; Megarbane et al. 2000). 
Heterozygous missense ZFPM2 mutations have been reported to contribute to some sporadic 
cases TOF patients (Pizzuti et al. 2003). CITED2 mutations are potential risk factors for CHD 
and account for about 2% of sporadic cases. Common symptoms include ASD, VSD, PS, and 
TOF (Sperling et al. 2005). ANKRD1 mutations have been reported as a possible cause of 
TAPVR (Cinquetti et al. 2008). 
Lots of signaling pathways are crucial for the heart development. Mutations in the 
components of these signaling pathways are also the common cause of non-syndromic CHD. 
NOTCH1 mutations can cause a wild range of non-syndromic cardiac defects, including 
BAV, AS, CoA, and HLHS (Garg et al. 2005; Mohamed et al. 2006; McBride et al. 2008) 
Apart from Alagille syndrome, NOTCH2 (McDaniell et al. 2006) and JAG1 (Bauer et al. 
2010) both cause non-syndromic CHD. Heterozygous CFC1 mutations in heterotaxy 
syndrome patients have been associated with outflow tract defects such as TGA and DORV 
(Goldmuntz et al. 2002). Loss-of-function mutations in GDF1 have been associated with 
congenital heart defects, contributing to cardiac defects ranging from TOF to TGA (Karkera 
et al. 2007). NODAL mutations have been identified and characterized in patients with 
heterotaxy, and isolated cardiovascular malformations (Mohapatra et al. 2009).  
The cardiomyocyte are the most important cell types in the heart, and contractile proteins 
take up a large part of cardiomyocyte. Problems in the contractile proteins usually results in 
the dysfunction of the cardiomyocyte. Mutations in contractile protein genes, including 
MYH6, MYH7, MYH11, MYBPC3, ACTC1, usually cause cardiomyopathies, such as 
hypertophic cardiomyopathy (HCM). However, some of these contractile genes sometimes 
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also associate with CHDs. For example, mutations in MYH6 is reported to associate with 
ASD (Ching et al. 2005); MYH7 mutations can cause septal defects and Ebstein’s Anomaly 
(Budde et al. 2007); ASD and PDA have been reported in severe HCM patients with 
homozygous mutations in MYBPC3 (Xin et al. 2007). 
2.3 OTHERS MECHANISM 
With the development of new detection technologies, other mechanisms for CHD, such 
as miRNAs, lncRNAs, histone modification, chromatin remodeling, copy number variations, 
have also being taken into account nowadays. A small fraction of CHDs can be explained by 
CNV, and it has been reported that the frequency of causal CNVs in non-syndromic CHD 
populations is lower than in syndromic CNV populations (3.6 vs 19%) (Breckpot et al. 2011). 
miRNAs, such as miR-1, miR-133, and miR-208, are reported to be important for heart 
development and cardiomyocyte differentiation (Chen et al. 2006; van Rooij et al. 2007). 
Baf60c, encoded by SMARCD3, is an essential component of Swi/Snf-like Brg1/Brm-
associated (BAF) chromatin remodeling complexes. It has been shown that this Baf60c 
containing chromatin remodeling complex plays a crucial role in heart developments (Lickert 
et al. 2004; Cai et al. 2013). However, most of these researches were based on mice and cell 
modeling, most of examination for real CHD patients is still focusing on the canonical 
genetic mutations. 
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3 CARDIOGENESIS IN MURINE 
The heart is a complex system composed of muscle and non-muscle cells. The main 
questions in heart development are, 1) what are the cells in the heart; 2) where do they come 
from; 3) how is their relationship with each other.  The ventricles take up the major part of 
the heart. But itself has complex cell type compositions. According to a previous study (Nag 
1980),  the ventricle of an adult rat heart contains approximately 65%~70% of non-
cardiomyocyte cells, while 30%~35% of cardiomyocytes. Assuming similar composition, 
cardiomyocytes take up about 30% of an adult heart. Through extensive lineage studies, three 
major heart progenitor populations have been found: cardiogenic mesoderm cells, the pro-
epicardium and cardiac neural crest cells (Brade et al. 2013). The cardiac mesoderm cells are 
of particular interest, as they are the main contributors to the cardiomyocytes. 
3.1 HEART DEVELOPMENT WITH CARDIAC PROGENITORS 
Cardiac mesoderm precursors are among the first cells that ingress through the primitive 
streak during gastrulation. After the ingression, these cardiac mesoderm cells migrate away 
from the primitive streak toward the anterior, and form the cardiac crescent on E7.5. 
On E8 the cardiac crescent folds inwards and fuses at the midline and gives rise to the 
FHF-derived linear heart tube. At this stage, the linear heart tube starts to beat. This linear 
heart tube is constructed with two layers of cells: outside is a cardiomyocyte layer called the 
myocardium and inside is an endothelial layer called the endocardium layer. Before the 
embryo turns, the linear heart tube loops to the right and start to bulge. This linear heart tube 
expands by self-proliferation and the integration of the SHF progenitors that are moving in 
the arterial and venous poles of the linear heart.  
On E9.5, the preliminary left and right ventricles are visible and keep ballooning. The 
atrioventricular canal, the septum between atria and ventricle, starts to form at this stage. At 
this stage, the freely floating pro-epicardial cell vesicles attach to the naked myocardium, 
starting at the atrioventricular canal region. 
On E10.5, the primitive shape of the four chambers has formed.  
On E11, the ventricular septum begins to form. The cardiac neural crest cells 
differentiate into aortic smooth muscle cells and the aorticopulmonary septum cells. These 
cells reshape the outflow tract into aortic and pulmonary trunks by providing signals as well 
as cells for these cardiac structures.  
By E11.5, the epithelial cell sheet derived from pro-epicardial cells will have covered the 
whole heart. On E11.5-13.5, some of epicardial cells undergo an epithelial-mesenchymal 
transition and differentiate toward various cell types, such as coronary vasculature and 
cardiac fibroblast. 
On E14, the four chambers and the septum between them have formed.  
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The movement of these progenitors are recently possible to be track in-real time in an ex-
vivo culture (McDole et al.). However, the genetic programs govern their activity remains 
elusive. To identify the cardiogenesis genetic program in mice, the lots of loss-of-function 
genetic experiments have been performed and have provided important clues. 
3.2 THE GENE LANGUAGE OF HEART DEVELOPMENT 
Through decades of research, the studies of some specific genes have provided us lots of 
insights about heart development. Some of these genes are identified as markers for important 
progenitor pools that are crucial for cardiogenesis. As these mark genes become the 
foundation of our current understand of cardiogenesis, they themselves form a language 
describing the molecular process of cardiogenesis.  
Mesp1&2 
The basic helix-loop-helix transcription factor Mesp1 marks the cardiac mesoderm 
progenitors. Disruption of the Mesp1 gene in mice leads to aberrant heart morphogenesis, 
resulting in cardiac bifida (Saga 1998). Mesp1 and Mesp2 double-knockout embryos died 
around 9.5 days postcoitum without developing any posterior structures such as heart, somite 
or gut (Kitajima et al. 2000). β-gal/lacZ lineage tracing shows the Mesp1-expressing cells 
migrate out from the primitive streak and are incorporated into the head mesenchyme and 
form the heart field (Saga et al. 1999). Clonal analysis of Mesp1-expressing cells 
demonstrates that two temporally distinct pools of Mesp1 progenitors sequentially give rise to 
the FHF and then the SHF progenitors (Lescroart et al. 2014). It has been estimated that ~244 
± 26 Mesp1 progenitors contributed to heart development (Chabab et al. 2016).  
Isl1 
LIM homeodomain transcription factor Isl1 marks the second heart field (SHF) 
progenitors. Hearts of mice lacking Isl1 are completely missing the outflow tract, right 
ventricle, and much of the atria (Cai et al. 2003). Further studies showed that these Isl1+ 
progenitors could be found in postnatal rat, mouse and human myocardium (Laugwitz et al. 
2005). During the heart development, these progenitors contributed to various cell lineages 
within the heart, such as cardiomyocytes of the right ventricle and atria as well as vascular 
smooth muscle and endothelial cells (Moretti et al. 2006). Later studies showed that these 
progenitors could ultimately generate a series of rare, transient Isl1+ ventricular heart muscle 
progenitors that are completely committed to the ventricular muscle fate (Domian et al. 
2009).  
Nkx2-5 
NK2 homebox 5, Nkx2-5 is expressed in both the first heart field (FHF) and SHF. Nkx2-
5-/- mice embryos showed arrest of cardiac development after looping and poor development 
of blood vessels (Tanaka et al. 1999). In the heart of adult chimeric mice generated from 
Nkx2-5 null mESCs, there were almost no mESCs-derived cardiomyocytes (Tanaka et al. 
1999). The single ventricle-like chamber of Nkx2-5 null embryos is correlated to the normal 
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left ventricle and mainly derived from the first heart field (Prall et al. 2007). In Nkx2-5-null 
embryos, Isl1 persisted in cardiomyocytes of the late cardiac crescent and heart tube, 
suggesting a role of Nkx2-5 as a SHF suppressor (Prall et al. 2007). 
Gata4  
The zinc finger transcription factor Gata4 is expressed in precardiogeneic splanchnic 
mesoderm at early heart development stage. Gata4 null mice arrests in development between 
E7.0 and E9.5.  Mutant embryos generated two independent heart tubes. But no random 
looping was observed in contract to Mesp1 knock out mice. (Molkentin et al. 1997) 
Mef2c 
The myocyte enhancer factor Mef2c is expressed in cardiac precursor cells before the 
formation of the linear heart tube. Mice homozygous for a null mutation of Mef2c have 
cardiac morphogenesis defects, the heart tube fails to loop, and the future right ventricle fails 
to form. At the molecular level, a subset of cardiac genes, such as Hand2, was not expressed 
normally. (Lin et al. 1997) 
Tbx1/Tbx5/Tbx20 
Tbx1+/- mice have a high incidence of cardiac outflow tract anomalies. Tbx1-/- mice 
displayed a wide range of developmental anomalies. As a mice model for the human 
DiGeorge syndromic CHD, the mutant mice showed almost all of the common DiGeorge 
syndrome features, including hypoplasia of the thymus and parathyroid glands, cardiac 
outflow tract abnormalities, abnormal facial structures, abnormal vertebrae and cleft 
palate.(Jerome and Papaioannou 2001) 
Tbx5-/+ mice were used to model Holt-Oram syndrome and have cardiac and forelimb 
abnormalities. Enlarged hearts were found in 8-week-old Tbx5-/+ mice. Both atria were dilated 
and the ventricles had a bulbous appearance. Tbx5-/- mice have severe hypoplasia of posterior 
domains in the developing heart. (Bruneau et al. 2001) 
Tbx20-null mice exhibit severely hypoplastic hearts and Tbx2 expresses throughout the 
heart, which is normally restricted to outflow tract and atrioventricular canal. The hearts of 
Tbx20 mutant mice were unlooped and severely hypoplastic (Cai et al. 2005). In another 
report, the Tbx20 mutant hearts had a distinct additional compartment in the outflow region 
became progressively obvious in mutant hearts, resulting by E9.5 in a heart tube with two 
small chamber-like swellings separated by a circumferential sulcus (Stennard et al. 2005).  
Hand1&2 
During mouse heart development, Hand1 and Hand2 are expressed in a complementary 
fashion and are restricted to segments of the heart fated to form the right and left ventricles. 
Targeted gene deletion of Hand2 in mouse embryos resulted in embryonic lethality at E10.5. 
Hand2 is required for formation of the right ventricle of the heart and the aortic arch arteries 
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(Srivastava et al. 1997). Hand1 null mice died between E8.5 and E9.5, and the heart 
development did not progress beyond the cardiac-looping stage (Thomas et al. 1998). 
Foxp4/ Foxh1/ Foxc1&2 
In Foxp4 mutant embryonic mice, each bilateral heart-forming region is capable of 
developing into a highly differentiated four-chambered mammalian heart in the absence of 
midline fusion (Li et al. 2004).  
Foxh1-/- mutant mouse embryos from a primitive heart tube, but fail to form out flow 
tract and right ventricle and display loss of outer curvature markers of future working 
myocardium (von Both et al. 2004). 
Single Foxc1 or Foxc2 mutants, compound Foxc1+/-; Foxc2+/- and Foxc1-/-; Foxc2+/- 
mutants exhibited no obvious abnormalities in the formation of the OFT and RV at E9.0. 
Other compound Foxc1; Foxc2 mutants have a wide spectrum of cardiac abnormalities, 
including hypoplasia or lack of the outflow tract (OFT) and right ventricle as well as the 
inflow tract, dysplasia of the OFT and atrioventricular cushions, and abnormal formation of 
the epicardium, in a dose-dependent manner. Compound Foxc1-/-; Foxc2-/- mutants die around 
E9.5. (Seo and Kume 2006) 
T 
The classical mouse mutation brachyury (‘‘short tail’’) was first described in 1927. 
Heterozygotes for null alleles of Brachyury have short tails and mild skeletal defects due to 
haploinsufficiency. Homozygous T-null mice have severe developmental disorders, such as 
defective mesoderm formation and regression of the notochord, and they usually die before 
E10 (Meisler 1997). The hearts of all T-null mice have some morphological abnormality. The 
heart looping inversion occurs in T-null mice at a chance of 50%. Aberrant expression of 
both the lefty genes and nodal is also observed. (King et al. 1998) 
Eomes 
The T-box gene Eomesodermin (Eomes) is essential for both trophoblast development 
and gastrulation. In chimaeras embryos, where the mutant cells intermingle with the wild 
type, mesoderm can be partially formed. Further examination showed the wild type cells had 
migrated efficiently through the primitive streak and become enriched in the mesoderm 
wings, whereas most mutant cells persist in the ectoderm. When injected into syngeneic 
hosts, mutant cells give rise to teratomas containing muscle, cartilage and haematopoietic 
tissue. These experiments showed that Eomes is not required for the differentiation of some 
mesodermal cell types, and indicates that the mutation may specifically affect the 
morphogenetic movement of cells from the epiblast into the primitive streak (Russ et al. 
2000). In another study, Eomes has been shown as the upstream of Mesp1 to specify cardiac 
mesoderm during mouse gastrulation (Costello et al. 2011). 
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Smad4/Nodal 
Smad4 null mice is embryonic lethal on E6.5-E8.5, without gastrulation (Yang et al. 
1998). But wild-type tetraploid morale rescues the gastrulation defect (Sirard et al. 1998). To 
characterize further the requirement of Smad4 during early gastrulation, Sox2Cre was used to 
specifically inactivate Smad4 in the epiblast. Mutant embryos form abundant extra-
embryonic mesoderm, including allantois, failure to pattern derivatives of the anterior 
primitive streak, a rudimentary heart, middle primitive streak derivatives such as somites and 
lateral plate mesoderm. The somites were fused across the midline. No definitive endoderm 
was derived from Smad4-deficient epiblast cells (Chu et al. 2004). Furthermore, the 
requirements of Smad4 in later stage of heart development is also found (Wang et al. 2005; 
Qi et al. 2007; Song et al. 2007).  
Mouse embryos deficient for the activity of Nodal fail to form both the mesoderm and 
the definitive endoderm. They also fail to specify the anterior visceral endoderm (AVE). 
Their study reveals that Nodal−/− epiblast cells express prematurely and ectopically molecular 
markers specific of anterior fate. (Camus et al. 2006) 
The loss-of-function approach to study the function of a specific gene in heart 
development is kind of like the stop reaction approach used in the Sanger sequencing. Every 
time a new defect shows up, we learn another critical step of heart development. When the 
mutant cells were building the heart, they would stop at the step required the function they 
have lost, relating the function with the corresponding gene. Take Isl1 for instant, the mutant 
embryo failed to form OFT and other structures, therefore OFT formation is critical step and 
Isl1 plays crucial role in it. Although the detail molecular mechanism is usually missing, the 
relationship between the function, OFT formation, and the gene, Isl1, is established. By 
examine these development defects, there are three major patterns: 1) failure in the early 
stage, like gastrulation; 2) the heart tube fails to loop or fuse; 3) the second heart field relative 
structures fail to form or are dysplastic. The first pattern is a differentiation issue, which is 
mainly modeled with ES differentiation. The second pattern is mainly a migration issue, 
which could sometimes be examined by marker, such Mesp1. But the third defect pattern 
currently are beyond the modeling capacity of ES system, since it could only be examined by 
formation real structures.   
3.3 MARKERS AND LINEAGES 
During embryo development, the pluripotent stem cells in the inner cell mass give rise to 
different precursor cells and increasingly restrict their lineage potential. Understanding the 
lineage through which the tissue and organs are formed is a fundamental question in 
developmental biology. To do that, we need two pieces of information, the cell identity and 
the lineage relationship between cells.  
The cell identity problem brings us to one of the most important concepts in 
developmental genetics, markers. Since the discovery of DNA, we learn every individual has 
its unique DNA codes. Similarly, we hope there is unique transcription profile for each 
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individual cell, or at least a subset of cells. Therefore, one marker for one cell type is a very 
attracted concept. Generally speaking, we can put markers into three categories. The first one 
is perfect marker, which can truly define a cell type. These markers would not express in any 
other cell types, such as MLC2v, which usually expresses only in the ventricular 
cardiomyocytes. However, even within the cells marked by the marker gene, depending the 
definition of cell type, there might be subtypes. Actually, perfect marker rarely exits, 
especially when it comes to the intermediates, like progenitors. The second type of marker is 
tissue restricted marker. Within the specified tissue, the marker gene expresses in some type 
of cell, but not in other cells. For instant, in the heart, ISL1 marks the second heart field 
progenitors (Cai et al. 2003). On the other hand, ISL1 also marks islet cells in the pancreas 
(Ahlgren et al. 1997), and motor neuron in the brain (Pfaff et al. 1996). The third type is 
temporal restricted marker. This type of marker labels the cells only at the specific time 
window. Outside of that window, it might label totally different cells. One of such marker is 
HCN4, which markers the first heart filed progenitor around E7.0, while, at later stages, it 
labels primarily the SAN node (Spater et al. 2013). In addition, the functional attribute of a 
maker can be classified as strong marker and weak marker. The strong marker plays a crucial 
role in the defined cells. Genetically disrupt such marker gene will result in the loss of the 
labeled cell population. On the hand, the loss function of a weak marker won’t affect the 
labeled cell populations, which usually happens to a surface marker. Taken together, the 
genetic markers allow us to define certain cells with some spatial-temporal restrictions, but 
they might not be functionally associated with the cell population. 
From the experiment aspect, to define a marker gene, the golden rule is the well-known 
Cre-loxP system. The Cre recombinase is a 38kD protein from P1 bacteriophage that 
catalyzes the recombination between two loxP sites (Hamilton and Abremski 1984). A 
typical marker lineage tracing experiment will knock-in Cre in the marker gene locus. When 
the gene activated during development, the Cre would faithfully express and modify the loxP 
containing reporter. As mentioned previous, a maker usually requires some spatial-temporal 
restriction. The tissue specificity is accomplished by knock-in the Cre into the maker gene 
loci, while the temporal control is achieved via modified Cre, such as CreERT2 (Feil et al. 
1997) and MerCerMer (Zhang et al. 1996), under the control of Tamoxifen at the chosen 
injection time point. 
A Cre reporter usually contains a STOP sequence flanked by two loxP sites, which 
would be excited when Cre is activated, allowing the downstream transcription. On the Cre 
reporter size, LacZ is one of the most comment reporter for Cre lines. The product of LacZ is 
β-galactosidase, which turns X-gal, an artificial substrate, into galactose and 4-Cl,3-Br indigo 
thus producing a deep blue color. The advantages of LacZ reporter is the lineage of marked 
cells are directly visible after X-gal treated. Another common Cre reporter is to replace the β-
galactosidase with fluorescent proteins, such EGFP, or tdTomato. But it is more common that 
combing both colors, the so-called mTmG reporter, which the loxP sites flank the tdTomato 
and STOP cascade, followed by the EGFP. This reporter gives a red background when the 
Cre is inactivated, and the marked lineage would have a distinct green fluoresce.   
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To get some information about dynamics of the marked lineage, stochastic labeling is 
very useful. The first and most well-known example is the brainbow (Livet et al. 2007). The 
loxP sites or/and its equivalents, and fluorescent proteins were arranged in a specific way that 
can generate diverse random colors upon Cre activation. The color difference between the 
progenies/marked cells allows the tracking of the induvial cells that give rise to difference 
tissues and structures. This type of in vivo clonal analyses provide lots of insights about how 
an organ is developed and regenerated (Gupta and Poss 2012), as well as how the tissue 
homeostatic is maintained (Snippert et al. 2010).  
Beside Cre-lox system, other similar tools have also been developed, such as FLP-FRT 
(Dymecki and Tomasiewicz 1998), and Dre-rox (Anastassiadis et al. 2009). However, these 
lineage tracing systems all require some prior knowledge about the maker gene of the lineage. 
To discover markers for sub-populations and study multiple lineages, newly developing tools 
such single-cell RNA-Seq (Lescroart et al. 2018) and CRISPR barcoding (Kalhor et al. 2018) 
go beyond the Cre-lox system and open a new chapter for the old subject of lineage study. 
Single-cell RNA-Seq profiles individual cells and project them onto a 2- or 3-dimension 
representation space with visual distant as a metric of the transcriptome similarity. With this 
approach, new sub types and bifurcation points can be found based on the transcription 
profile not just pre-existed markers. Pseudo-time and computational lineage can be extract 
from such datasets, and by examining the expression in the lineage branch new markers for 
that specific branch can be identified (Kester and van Oudenaarden 2018). CRISRP 
barcoding construct the lineage tree of the tissue of interested by analysis the mutations 
induced by Cas9 during development. These new technologies are still in their early 
development stage, the confidence level of their lineage conclusions is less than the canonical 
Cre-lox system, but they bring the hope to resolve the lineage mystery at large scale.  
Another fruit of thought comes from the long noncoding RNA (lncRNA). LncRNAs 
have been shown to be more tissue specific comparing to protein markers (Liu et al. 2016). 
The argument is the diversity of the tissue are more of the result of the diversity in the 
regulatory elements, while the protein machinery has not changed much in the mammalians 
evolution trees. Anyway, the importance of marker genes, coding or noncoding, in 
developmental biology and other branches will continues to growth and providing more and 
more vocabularies for the language of genes, hopefully one day the language of cells. 
3.4 DIFFERENCES BETWEEN MICE AND HUMANS 
The study based on mice model have gave us significant insight about the molecular 
mechanism of heart development. However, there are lots of difference between the human 
heart and mice’s. A mouse heart is created in just a couple of days, while the human heart is 
continuously built over several months. The physiology of human heart is quite different 
from mouse heart, including heart rate and blood presure. For example, in mouse the heart 
rate is usually 450-750bpm, while the human heart rate is usually 60-100bpm. The size of 
mice heart is about 1×0.5×0.3 cm3, while the human heart is about 13×8×5 cm3, which is 
more than 3000 times bigger (Hansson et al. 2009). The bigger the size is, the more cells are 
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allocated to build the heart, which also means the complexity of human cardiogenesis is 
much higher than mice’s. This implies a higher degree of progenitor proliferation in human 
cardiogenesis. To learn the authentic human cardiogenesis, we need to study the 
cardiogenesis using the human model. But our options are limited, one of them is the human 
pluripotency stem cells model. 
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4 CARDIOMYOCYTE FROM HPSC 
4.1 CARDIOMYOCYTE DIFFERENTIATION 
Human pluripotent stem cell (hPSC) includes human embryonic stem cell (hESC) and 
induced pluripotent stem cell (iPSC). The first hESC line was derived from human 
blastocysts in 1998 (Thomson et al. 1998). Human iPSC lines were first derived in 2007 by 
overexpression of key stem cell related transcriptions factors in somatic cells (Takahashi et al. 
2007; Yu et al. 2007). hPSC can self-renew indefinitely in culture while maintaining the 
ability to differentiate into the 3 primary germ layers, hence potentially any cell types in the 
human body. In principle, these cells are the ideal sources for many cell-based applications, 
such as, cell therapy, drug safety test, disease modeling, and other basic researches. However, 
to make full use of these cell sources, robust and efficient differentiation protocols for 
generating the cell types of interest are essential.  
Embryoid bodies (EB) are the three-dimensional aggregates formed in suspension by 
pluripotent stem cells. Cells in EBs differentiated to derivatives of the 3 primary germ layers. 
Different types of cells can be obtained by providing different development cues to these 
cells. The first successful EB-mediated differentiation of hESCs to cardiomyocytes was 
reported in 2001 using H9 hESC line. By plating EBs to 0.1% gelatin-coated culture dish, 
beating areas can be observed after 4 days after (Kehat et al. 2001). Comparable EB-based 
differentiation protocols were reported to generate cardiomyocytes from a variety of hESC 
lines: H1, H7, H9, H14 and hiPSC lines: IMR90 C1/4, iPS(Foreskin) C1/2 (Xu et al. 2002; 
He et al. 2003; Zhang et al. 2009). These EB-based differentiation protocols were difficult to 
reproduce and exhibited line-to-line variability in efficiency (Osafune et al. 2008), and have 
two addition issues that limits their applications: 1) the differentiation media and culture 
conditions were not chemically defined, using feeder cell layer for the culture, containing 
serum and other animal original components; 2) the EBs formed during the processes were 
highly variable in size, structure and composition.  After a few years’ research, serum and 
feeder free culture conditions were established (Ludwig et al. 2006a; Ludwig et al. 2006b; 
Chen et al. 2011). And lots progresses have been made in homogenizing the EB formation, 
such as spin EBs (Ng et al. 2005; Burridge et al. 2007), micro well EBs (Khademhosseini et 
al. 2006; Mohr et al. 2006) and micro patterned EBs (Peerani et al. 2007; Bauwens et al. 
2008). 
The second phase of cardiac differentiation begins with the replacement of the serum 
with growth factors in the differentiation media. Three major serum-free defined basic media 
for cardiac differentiation were developed, including APEL from Stem Cell Technologies, 
StemPro-34 and RPMI from Thermo Fisher Scientific/life technology. A range of growth 
factors implicated in normal cardiac development have been tested, including BMP4, Activin 
A, FGF2, Wnt agonists and antagonists, and vascular endothelial growth factor. Growth 
factors based protocols still exhibit line-to-line variability. Different cell lines require 
different concentrations of Activin A and BMP4. However, by monitoring of KDRlow/KIT- 
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(Yang et al. 2008) or KDR+/PDGFRA+ (Kattman et al. 2011), the optimal concentrations of 
Activin A and BMP4 for each cell lines can be found, and high efficient cardiomyocytes 
differentiation to be achieved, about 50%~65%. 
EB methods have lots of drawbacks, such as low cardiomyocytes yield and 
heterogeneous in the differentiation product. An improved approach is monolayer-based 
method. hPSCs were first singularized and seeded on Matrigel or defined matrix-coated Petri 
dishes to produce a homogenized monolayer. When the cells were confluent, Activin A and 
BMP4 was sequentially added with defined RPMI/B27 medium. This method generated more 
than 30% cardiomyocytes in the H7 hESC line before optimization Activin A and BMP4 
concentration and cardiomyocytes can be enriched to around 80% with Percoll gradient 
centrifugation purification (Laflamme et al. 2007). However, this method still requires 
optimizations for different cell lines. One improvement for this protocol is to overlay 
Matrigel to the cells to produce thicken the mono cell layer, which is subsequently treated 
with Activin A, BMP4, and FGF2 in RPMI/B27-minus insulin medium to induce robust 
cardiomyocyte differentiation. This is known as the matrix-sandwich method (Zhang et al. 
2012). The matrix-sandwich method generated CMs with high purity (up to 98%) and high 
yield (up to 11 CMs/input hPSC) from multiple hPSC lines, including H1, H9, IMR90 C4, 
DF6-9-9T, DF19-9-7T, DF19-9-11T. 
The next break-through in cardiomyocyte differentiation comes from the replacement of 
growth factors stimulation with chemical stimulation. By adding a Gsk3 inhibitor to activate 
canonical WNT/β-catenin signaling pathway and later a PORCN inhibitor to inhibit WNT 
signaling pathway, cardiomyocytes can be robustly generated when these chemicals are 
added at the right time with the right concentration. This temporal modulation of WNT 
signaling pathway with small chemicals is also known as the GiWi method (Lian et al. 2013). 
Combing the GiWi method and some chemically defined hPSC culture media, a chemically 
defined differentiation protocol was developed (Burridge et al. 2014). From media, coating 
matrix to differentiation stimulus, all the reagents are chemically defined, opening the doors 
of producing clinical grade hPSC derived cardiomyocytes (hPSC-CMs). Later, the albumin-
free GiWi, named GiWi2, was developed, which further simplified the differentiation media 
with only RPMI and ascorbic acid (VC) (Lian et al. 2015). In another method, the basal 
differentiation medium is DMEM/F-12 instead of RPMI, and albumin can be removed in the 
present of heparin (Lin et al. 2016). 
From the “spontaneous” EB protocol in 2001 to the total chemically defined protocol in 
2014, the differentiation efficiency increased from less than 1% to 95%.  After a decade and 
half’s effort, the in vitro cardiogenesis model is finally established. The unlimited supply of 
hPSCs and robust and high efficient differentiation protocols enable a wide range of 
applications of cardiomyocyte differentiation, such as disease modeling, cardiotoxicity 
screening, drug discovery, human cardiogenesis research and cell therapy relative research. 
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4.2 CARDIOMYOCYTE MATURATION 
There are a number of reasons why producing mature cardiomyocytes are important. But 
the primary reason is, compared to mice and the model organism, the access of adult human 
cardiomyocytes for research is very limited. The mature hPSC-CMs are better proxy for the 
human cardiomyocytes than mice cardiomyocytes. Tests performed on the more mature 
cardiomyocytes are more relevant and reliable for developing new therapy, testing drug 
safety, and modeling heart diseases. However, the status quo of the hPSC-CM is they 
resemble the immature cardiomyocytes and methods for improving the maturation of hPSC-
CMs are underdeveloped. Comparing to the adult cardiomyocytes, the hPSC-CMs are 
different in many ways, such as morphology, electrophysiology, calcium handling, 
ultrastructure, metabolism et.al.  
In terms of morphology, an adult cardiomyocyte is much larger and cylindrical shape, 
about 150µm ´ 10µm, and most of them are bi- or multinucleated. hPSC-CM is smaller and 
spherical, about 5~10µm in early hPSC-CM and 30µm ´ 10µm in late hPSC-CM, and most 
of them are mono-nucleated (Robertson et al. 2013). In adult CM, the contractile machinery, 
mainly myofibril, takes up 40%~52% of the cytoplasm and mitochondria take up 15%~25% 
(Tashiro et al. 1990; Barth et al. 1992). hPSC-CM has much lower cytoplasm-nuclear volume 
ratio and the machinery and mitochondrial take up much less space of the cell (Robertson et 
al. 2013).  
The differences between hPSC-CM and adult CM in electrophysiology are well 
documented. The adult CM has maximum diastolic potential about -85mV~ -90mV 
(Robertson et al. 2013; Yang et al. 2014), while hPSC-CM is about -30mV at early stage and 
advances to -60mV to -75mV at late stage (Robertson et al. 2013). The action potential 
duration at 90% of repolarization (APD90) is 250~400ms in hPSC-CM, which is longer than 
~213ms in adult CMs (Hoekstra et al. 2012). The biggest difference is the maximum rate of 
depolarization (max dV/dt, Vmax), adult CM is 215~300V/s, while hPSC-CM has only 
10~40V/s at late stage (Hoekstra et al. 2012; Robertson et al. 2013). And the propagation of 
the electrical signal is 20cm/s in hPSC-CM (Lee et al. 2012) and 60cm/s in adult CM 
(Veerman et al. 2015). 
Calcium handling is important for cardiomyocytes, connecting the electrical signal with 
the contractility. In the hPSC-CMs, a crucial structure is usually missing, transverse tubules 
or T-tubules. This structure enables special and functional coupling of the L-type calcium 
channel (CACNA1S) and cardiac ryanodine receptor (RYR2). Lack of this structure results in 
U-shape Calcium wave fronts, in contrast to uniform calcium wave front in the adult CMs 
(Lieu et al. 2009). In addition, the expression of some sarcoplasmic reticulum proteins, such 
as Caveolin-3 (CAV3), Calsequestrin (CSQ), and amphiphysin-2 (BIN1), are lower in hPSC-
CMs (Dolnikov et al. 2006; Synnergren et al. 2012). 
The force generation unit in cardiomyocyte are the sarcomeres, a structure repeating 
itself between the two Z-lines. In adult CMs, all the prominent myofilament regions, such as 
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Z-line, I-band, A-band, H-zone and M-line, are present, suggesting the formation of 
overlapping and non-overlapping myofilaments. In contrast, M-lines are usually missing in 
hPSC-CM, as in vivo they do not develop before the neonatal period (Scuderi and Butcher 
2017), indicating the immaturity of the hPSC-CM. 
Another difference between the adult CMs and hPSC-CMs is the metabolic pathways. 
The adult CMs use the fatty acid oxidation metabolism, while hPSC-CMs use mostly 
glycolysis. However, the metabolism switch has already begun in hPSC-CMs, and has been 
used for large-scale cardiomyocyte purification (Tohyama et al. 2013). Other differences, 
such contractile force, gap junction distribution, responses to b-adrenergic stimulation, have 
been systematic reviewed by Yang et al. 2014.  
To improve the maturation status of hPSC-CMs, lots approaches have employed, 
including electrical stimulation, mechanical stimulation, biochemical stimulation, different 
extracellular matrix, co-culture with different cells, force gene expression. However, so far, 
these methods can only improve the maturation of hPSC-CM from certain aspects. One 
example of such studies is reported recently. Applying both electrical and mechanical 
stimulation at the early stage of hPSC-CM can induce the formation of T-tube, but the 
electromechanical properties did not achieve the stage of maturity seen in adult human 
myocardium under such stimulation (Ronaldson-Bouchard et al. 2018). To achieve a satisfied 
maturation state, lots of works are still needed to be done.  
4.3 CARDIOMYOCYTE SUBTYPES 
Most of the differentiation protocols yield three types of cardiomyocytes according their 
action potential characters: ventricular-like, atrial-like and pacemaker-like cardiomyocytes. 
The variables are the composition of the three types cardiomyocytes. A very nature question 
how to enrich different types of cardiomyocytes. Since the loss of ventricular cardiomyocytes 
during heart attack or nature aging can barely regenerate (Bergmann et al. 2009), ventricular 
cardiomyocytes are in great demands for the cell replacement therapy. And pacemaker 
cardiomyocytes have the potential of being engineered into a biological artificial pacemaker. 
Besides the electrophysiology features, atrial and ventricular CMs have their distinct 
genetic markers. MLC2v (MYL2) specifically marks the ventricular CMs, while MLC2a 
(MYL7) marks both atrial and ventricular CMs at early stage, but restrict to the atrial CMs at 
later stage. With these markers, protocols have been developed to enrich both the ventricular 
and atrial CMs. Previous study has shown the activation of retinoic acid (RA) signaling 
increase the atrial CM population, while inhibition of this pathway increases the ventricular 
CM population (Zhang et al. 2011). And further study shown, the atrial and ventricular CMs 
are from different mesoderm sub-populations: ALDH+ mesoderm give rise to atrial CMs; 
and CD235a (GYPA) marked mesoderm becomes ventricular CMs (Lee et al. 2017). 
The advance in producing pacemaker CMs is the conversion approach. Inspired by the 
study in neonatal rat ventricular myocytes (NRVM) that Tbx18 is able to convert NRVMs 
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into pacemaker like cells both in vitro and in vivo (Kapoor et al. 2013; Hu et al. 2014), 
ventricular cardiomyocyte can be first derived from hPSC, then convert to pacemaker 
cardiomyocyte by overexpressing TBX18 (Gorabi et al. 2018). Similar trans-differentiation 
by overexpression approaches have also been tried out, such as, overexpressing SHOX2 
(Ionta et al. 2015), overexpressing engineered HCN1 channel (Chan et al. 2017). 
4.4 DISEASE MODELING WITH HUMAN PSC-CMS 
Disease modeling is one of the many applications of hPSC-CMs. Given the challenges of 
genome editing in hESCs before CRISPR technology, most disease modeling at the early 
days were using iPSCs from the patients and their relatives. The mutations occurred in the ion 
channels are among the first diseases that being model by iPSCs, such as KCNQ1 R190Q 
causes long-QT syndrome (Moretti et al. 2010), a missense mutation in the L-type calcium 
channel CaV1.2 leads to long-QT with Timothy syndrome (Yazawa et al. 2011), KCNH2 
A614V results abnormal action potential in type 2 LQTS (Itzhaki et al. 2011), SCN5A 
1975insD/+ results sodium current problem (Davis et al. 2012), PLN R14del mutation 
induces Ca++ handling abnormalities (Karakikes et al. 2015). The effects of these mutations 
are relatively simple to measure since once the mutated channels were expressed in the 
hPSC-CM, the phenotype can be directly assay through electrophysiology studies or calcium 
measurement.  
The second type of diseases being modeled by iPSC-CM are mutations that causes tissue 
abnormally. One of such examples is TBX20 Y317* T262M mutation cause left ventricular 
non-compaction cardiomyopathy (Kodo et al. 2016). And the phenotype reveal by this study 
is the mutation cause ectopic activation of TGF-β signaling, which causes a cardiomyocyte 
proliferation defect in vivo. This phenotype is at the signaling pathway level, only indirectly 
suggesting a possible cause of the symptom in patient. Another similar case is the MYH7 
A663H mutation results in contractile arrhythmia at the cellular level, while in patient, this 
mutation associated with familial hypertrophic cardiomyopathy (Lan et al. 2013).  
Another interesting disease modeling cases is the arrhythmogenic right ventricular 
dysplasia (ARVD). ARVD patients are usually carrying mutation in the desmosome proteins: 
PKP2, DSC2, DSG2, DSP, JUP. The advance stage symptoms are progressive replacement 
of right ventricular myocytes with fatty or fibrofatty tissue. To model this disease with hPSC-
CM is to demonstrate the mutants hPSC-CMs are more susceptible to turn into adipocytes. 
iPSC-CMs from patients with PKP2 c.2484C>T mutation are indeed easier to become 
adipocytes, but only under the adipogenic condition (Kim et al. 2013). This study suggests 
that to reveal the phenotype in cell models, stress challenges are also often required. 
The next level of disease modeling with hPSC-CM would require the formation of 
simple tissue. By ‘simple’, I mean the in-vitro tissues that are not vascularized, such as 
engineered heart tissues (EHT) (Breckwoldt et al. 2017). Barth syndrome (BTHS), a 
mitochondrial disorder caused by mutation in TAZ. BTHS is characterized by depletion of 
mature cardiolipin and accumulation of an immature form, monolysocardiolipin. These 
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phenotypes can be directly measured in cellular assay. The challenge is the myopathy part. 
By engineering a muscular thin film (MTF) from both wild type and mutant hPSC-CMs, 
diastolic and peak systolic stresses and Twitch stress can be calculated from the movies of 
contracting MTFs (Wang et al. 2014a). And these two parameters are useful for scoring the 
BTHS myopathy.  
4.5 TRANSPLANTATIONS 
The promise of cell therapy is one of main driven forces of the hPSC-CM research. The 
first tie of repairing the damage from myocardial infarction with cells were happen during the 
90’s last century (Marelli et al. 1992; Koh et al. 1993; Chiu et al. 1995). Since then, lots 
different cells have been used for transplantation in the hope to repaired an infarcted heart, 
such as skeletal myoblasts (Murry et al. 1996; Jain et al. 2001; Leobon et al. 2003), 
fetal/neonatal cardiomyocytes (Leor et al. 1996; Li et al. 1996; Scorsin et al. 2000), 
fibroblasts (Hutcheson et al. 2000), smooth muscle cells (Yasuda et al. 2005), hematopoietic 
stem cells (Penn et al. 2002; Nygren et al. 2004), mesenchymal stem cells (Toma et al. 2002), 
endothelial cells (Kocher et al. 2001), adult cardiac progenitor cells (Beltrami et al. 2003; Oh 
et al. 2003),and hPSC-CMs (Klug et al. 1996; Kehat et al. 2001; Xu et al. 2002; Laflamme et 
al. 2005; Laflamme et al. 2007; Robey et al. 2008; Fernandes et al. 2010; Shiba et al. 2012; 
Chong et al. 2014; Ye et al. 2014; Liu et al. 2018). Among them, hPSC-CM transplantation 
has the most impact so far, and has been systematically studied across several species, and 
goes all the way to non-human primary studies. 
Engraftment is the critical step for cell therapy. In the scenario of cell transplantation into 
myocardium, engraftment involves cell survival, migration, proliferation, differentiation, 
maturation, integration, electrical coupling, and vascularization. Once the cells are buried in 
the heart, the possible controls over the cells are very limited. These cells have to complete a 
wild range of complicate tasks pretty much on their own. Survival is the first obstacle, only a 
fraction of the cells transplanted can survival for more than a few weeks (Robey et al. 2008). 
For hPSC-CMs, there are three principal pathways that reduce the survival of the transplanted 
cells: ischemia, anoikis, and inflammation-related factors. And pro-survival strategies have 
been deployed, such as, heat-shocked, incubating with IGF1 and cyclosporine A, supplying 
the suspension buffer with Matrigel, ZVAD, Bcl-XL BH4, IGF1, CsA, pinacidil (Laflamme 
et al. 2007; Shiba et al. 2012). Compared to hPSC-CM transplantation, the progenitors should 
have better survival rate and their proliferation ability is much better than hPSC-CMs. 
Unfortunately, the identities of the progenitors are varied, and the engraftment outcome 
depends heavily on the types of progenitors input in.  
The next phase of the challenges for the progenitors are migration, proliferation and 
differentiation. In the moycardiac infaction (MI) heart, the infracted area needs to be invaded 
by these progenitors. They need to know where to go and where to stop. And at the same 
time, these progenitor is facing the choice between proliferation and differentiation. If the 
progenitors differentiate too early, there might not be enough cardiomyocyte to improve the 
heart wall function. On the other hand, if the progenitors proliferate too much, they might 
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lose the ability to differentiate into cardiomyocytes. The proliferation-differentiation balance 
will add another factor to determining the among of progenitors required for the 
transplantation.  
The hPSC-CMs do not have much proliferation ability and no need to worry about 
differentiation. But both hPSC-CM and progenitor transplantations would have the 
cardiomyocyte maturation step. The immature cardiomyocytes inside the ventricular myocyte 
wall can cause problems, such arrhythmia, insufficient force generations. Recent study has 
shown the stimulations at the early stage helps the hPSC-CM maturation more than that at the 
later stage (Ronaldson-Bouchard et al. 2018). The moving ventricular myocyte wall provides 
the stimulations for the hPSC-CMs, either from the direct transplantation or the freshly 
differentiated from progenitors. In this context, progenitors might yield a better result in 
terms maturation. But a detail comparison study is still missing till this day.  
The integration challenge is how the transplanted cells connect to the native cells, 
especially the cardiomyocytes. The connection is usually demonstrated by the expression of 
connexins, such as CX40 and CX43. These membrane proteins form gap-junction channels 
between cardiomyocytes allowing the transmission of signaling molecules and ions to diffuse 
between cells. Another integration challenge is the dissolution of fibrosis. The extracellular 
matrix (ECM) from the fibrosis makes it difficult for the hPSC-CM functionally connect to 
the native tissue. The transplanted cell would have to find a way to remove these ECMs, 
restoring the electrical and mechanical property of the tissue. And yet, such study remains 
difficult to perform. 
The long-term survival of a thick graft depends on the oxygen and nutrition supply, 
which make vascularization a critical requirement.  Mature cardiomyocytes use the fatty acid 
oxidation metabolism. They are very sensitive to oxygen level. The physical diffusion of 
oxygen is around 150µm, which means any graft more than 10-cells thick require supply 
from capillary. One strategy is to mix endothelial cell with hPSC-CM to form a network 
hoping to connect with the vessel network from the host. Another strategy is to recruit the 
vessel network into the graft either by the cues secreted by the transplanted cells or external 
chemicals, such as VEGF, added to the cells when transplanted. 
Transplanting hPSC-CM or progenitors as cell therapy is still in their early research 
stage. Most of the time, all we can do is to put some cells into the animal heart hoping 
something nice would happen. When it happens or dose not, we learn something. By 
accumulating these information piece by piece, there is still hope to truly pre-program the 
cells to accomplish the complicated heart regeneration tasks. 
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5 GENOMIC TECHNOLOGY 
During my study two big technology evolutions happen in biology: the rapid 
development of mass parallel sequencing and CRISPR-Cas9 genome editing. Both 
technologies are focusing on the genome: one is about reading the genome and the other is 
about writing it. In this section, we briefly introduce the tools used in our studies. 
5.1 MASSIVE PARALLEL SEQUENCING 
Illumina sequencer is the main sequencing platform in our studies. A basic knowledge of 
how the sequencer works can help to understand of library preparations procedure. In an 
illumina sequencer, the reactions take place on the surface of a flow cell. From the DNA 
fragments to digital letters, there are two main steps: template amplification and sequencing 
by synthesis.  
The template amplification strategy in illumina machine is called solid-phase bridge 
amplification. First, the templates are constructed by adding the adapters to both ends of the 
DNA fragments. Then, these templates are load into the illumina flow cell, on the surface of 
which were pre-coated with the two types of single strand DNAs that are able to bind to the 
adapters on the template. Third, during the amplification process, the single strand DNAs on 
the surface serves as the primers for the PCR reaction.  Finally, the elongated DNAs carries 
the information of the template and can bind to the other primer on the surface, forming a 
bridge like structure. After dozens of reactions, the spot where a template has bound to will 
form a cluster containing the DNAs with the same sequence. This spot amplifies the signal 
from sequencing-by-synthesis to the detectable level.  
The second step is to read out the DNA sequence in the spot. This is done by sequencing 
by synthesis. The key component of this process is the fluorophore-labelled, terminally 
blocked nucleotide. The fluorophore enables the identification of the incorporated nucleotide 
through imaging. The terminally block only allow adding one nucleotide at each reaction. 
Moreover, after the readout, the fluorophore can be cleaved exposing the 3’-OH group. Thus, 
the blockage is removed, and new nucleotide can be appended at the end. Combing these 
smart designs, the DNA sequence can be read out one nucleotide by one nucleotide. Though 
the process is slow, the throughput is high, as millions of spots can be imaged at one reaction 
cycle. 
There is trip worth to mention is how to add adaptors to the DNA fragments to construct 
the sequencing compatible template. For the DNA fragments whose sequence are partially 
known, adaptors can be simply added by a simple PCR. For the unknown fragments, random 
primers or T-A ligations can be used to add the adaptors. But the efficiencies of these 
methods are not so good and often large amount of input sample material is required. One of 
the solutions is Tn5 transposase. Like other transposase, Tn5 operates in cut-and-paste 
manner. After Tn5 is loaded with adaptors, it can just randomly cut the long DNA chain into 
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small fragments and paste the adaptors at the cut site (Picelli et al. 2014). The combination of 
the two procedure is called Tagmentation. Because this technique the efficiency of adding 
adaptors are much high. Materials from even a single cell is enough to produce the sequence 
library. 
With all these technical innovations, breakthroughs in DNA sequencing significantly 
lower the cost of genome-scale sequencing and make many new applications possible, such 
as RNA-Seq, ChIP-seq, DNase-Seq, FAIRE-Seq, ATAC-Seq, RRBS. These new applications 
add layers after layers new information on top of the human genome. RNA-Seq provides the 
transcriptome map. ChIP-Seq provides histone modification map and identify some 
transcription binding sites. DNase-Seq and FAIRE-Seq provide information about the open 
chromatins. ATAC-Seq shows the interactions of the chromatins. RRBS shows the 
methylation status of the CpG islands. Beside these standardized application, knowing the 
basic sequencing principle also allow us to develop new applications. Barcode back tracking 
used in the CRISPR screen is one of such examples.   
5.2 TRANSGENIC TOOLS FOR HPSC 
Transgenic tools are very useful when we just want to deliver some functional DNA 
fragment in the genome without targeting specific locus. Lentivirus and PiggyBac transposon 
system are two of such tools. When generating the mutant cell library, low titer Lentivirus 
was used to deliver the sgRNAs into the hPSCs avoiding multiple integration. In terms of the 
deliver efficiency in hPSCs, lentivirus is lower than PiggyBac, which is more suitable for 
library generation. On the hand, for overexpression purpose, PiggyBac system is able deliver 
large cargo at high efficiency and very simple to used. Below, we have included some basic 
information about these two transgenic tools. 
Lentiviruses are a subclass of retroviruses. Retroviruses are useful for ex-vivo delivery of 
somatic cells because they can be linearly insert into host cell genome. However, they have a 
few problems, such as the low in-vivo efficiency, immunogenic problems, the inability to 
transduce the non-dividing cells. Lentiviruses distinct itself from other retroviruses with their 
ability to naturally integrate to the genome of non-dividing cells. It has been used as tool for 
engineering transgenic cell lines due to the high-efficiency infection of dividing and non-
dividing cells, long-term stable expression of a transgene, low immunogenicity and the ability 
to accommodate medium size transgenes with 8kb shuttle capacity. 
The drawback of this tool is the safety issues. To transfect the cells, virus must be first 
produced. To increase the safety, the components necessary for virus production are split 
across multiple plasmids: transfer plasmid, packaging plasmid and envelope plasmid. 
Without the packaging and envelope components in genetic material inside the virus, it 
cannot replicate itself making it safer to work with. But there is still some small chance that 
the packaging and envelope can rejoin the transfer DNA sequence. The third generation of 
lentiviruses tool further separate the components, increasing from three-plasmid system to 
four-plasmid system. 
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DNA transposons are recently used as a molecular tool for inserting foreign DNA to the 
host cells. DNA transposons are genetic elements that can relocate between genomic sites by 
a “cut and paste” mechanism. The system function in pairs. It requires the transposon 
sequence and the corresponding transposase, the enzyme that moves the sequences around 
the genome. Sleeping Beauty was the first DNA transposon system shown to be functional in 
mammalian cells. Its transposition efficiency is relatively low and has strong “local hopping” 
tendency. The system widely used for engineering hPSCs is PiggyBac transposon system, 
which was isolated from insect. One important feature of the PiggyBac transposon is that it 
nearly always excises itself precisely and leaves no footprint behind. PiggyBac has 
significantly higher transposition activity in mammalian cell lines than Sleeping Beauty and 
Tol2.  
PiggyBac transposon system has serval advantages over the traditional lentivirus method 
in engineering new cell lines. First, the inserted DNA fragment can reach 100kb or more (Li 
et al. 2011), much higher than lentivirus. Second, the whole operation is DNA delivery and 
there is no need for virus production, purification and transfection. It is a much safer and 
easier system to work with. Third, the efficiency is much higher in hPSCs than lentivirus. 
Finally, there is an option that we can remove the inserted DNA fragment. By expressing a 
mutated form of transposase, which the insertion function is impaired, the inserted DNA 
fragments can be remove and more importantly sequence at insertion site can be perfectly 
restored. Because of these advantages, our main validation tool and rescue construct is 
PiggyBac based. 
5.3 GENOME EDITING IN HPSC 
Four genome editing technologies have been developed, including homology 
recombination (Gordon et al. 1980), zinc-finger nucleases (Kim et al. 1996), transcription 
activator-like effector nucleases (Hockemeyer et al. 2011), and the RNA-guided 
CRISPR/Cas9 system (Cong et al. 2013; Mali et al. 2013).  
Since genome editing via homology recombination (HR) is low efficiency and time 
consuming, only a few cases have been reported. The first genome editing case in hPSCs was 
reported in 2003, which generated HPRT1 knock-out and POU5F1-GFP knock-in hESC lines 
(Zwaka and Thomson 2003). To study cardiogenesis using hESC model, GFP was knocked 
in to the early mesoderm marker gene MIXL1 and pan cardiac marker gene NKX2-5 in 
hESCs. The MIXL1-GFP knock-in hESC line was used to optimize mesoderm induction from 
hESCs (Davis et al. 2008). The NKX2-5-GFP knock-in hESC line was used to optimize 
cardiomyocyte differentiation from hESCs (Elliott et al. 2011). Based on the pre-existed 
NKX2-5-GFP hESC line, another fluoresce protein mCherry was inserted into the MESP1 
locus creating the first dual-reported hESC line (Den Hartogh et al. 2015). To determine the 
lineage derivatives from the second heart field progenitors, Cre was knocked in to the locus 
of ISL1, a marker gene for second heart field progenitor (Bu et al. 2009). 
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DAN double strand breaks (DSBs) are the key for genome editing. There are two general 
DSB repairing pathways: the Non-Homologous End Joining (NHEJ) DNA repair pathway or 
the Homology Directed Repair (HDR) pathway. In the present of suitable repair template, 
usual from an externally introduced donor vector, the DSB is repaired by the HDR pathways. 
In this repairing pathway, the sequence in the template will be transferred precisely to 
targeted region. By providing DNA templates with designed features, the feature sequence 
can be insert precisely into the gene loci in the genome. The NHEJ DNA repair pathway is 
activated when DSB occurs in the absence of a suitable repair template. With NHEJ repair 
pathway, a small number, sometimes a couple hundreds, of nucleotides are either randomly 
inserted or deleted at the DSB site.  These indels may cause the shifting of open reading 
frame (ORF) of the gene, or introducing a premature stop codon. Any of these outcomes from 
the NHEJ repair pathway will disrupt the normal expression target gene, achieving the loss-
of-function of the targeted gene. For decades, the major efforts in genome editing have been 
focusing on making DSB at specific locus. ZFNs, TALENs and CRISPR-Cas9 systems were 
developed as tools for genome editing. 
Zinc-finger (ZF) and Transcription activator-like effector (TALE) are a class of versatile 
and programmable DNA-binding proteins. ZFs are stackable motifs of ~30 amino acids that 
recognize approximately three base pairs of DNA. However, simply stacking the ZFs cannot 
reliably recognize longer sequences (Ramirez et al. 2008), which makes using ZFN to target 
arbitrate sequences difficult.  
TAL effector can recognize DNA sequence without the ZFNs’ problem. The difficulty 
lays in the assembly such plasmids, which contain lots of repeats. It takes 34 amino acids 
TAL motif to recognize a single base pair through contracts with amino acids 12 and 13, 
known as the repeat variable di-residue (VDR) (Boch et al. 2009).  
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR 
Associated (Cas) system was first discovered in bacteria and archaea (Bhaya et al. 2011; 
Terns and Terns 2011; Wiedenheft et al. 2012). This system has been reduced down to three 
core components: a specificity-determining crRNA, an auxiliary trans-activating crRNA 
(tracrRNA) and the CRISPR-associated nuclease Cas9. The crRNA contains the protospacer 
sequence, which is the most important sequence because this sequence guides the Cas9 
complex to complementary DNA locus in the genome. Additional sequences in the crRNA, 
allows the hybridization with the tracrRNA to form a crRNA-tracrRNA duplex. A fully 
functional crRNA-tracrRNA-Cas9 complex is formed when the RNA duplex joins together 
with nuclease Cas9, which contains domains homologous to both HNH and RuvC 
endonucleases (Jinek et al. 2012; Nishimasu et al. 2014). Once the complex position in the 
right loci, a DNA-RNA-protein complex is formed, and the Cas9 begins to cut the double 
strand DNA. The right loci are defined by the complementary of 20 nucleotides guide 
sequence in crRNAs RNA and the DNA, as well as the presence of an appropriate 
protospacer adjacent motif (PAM) sequence immediately downstream of the guide sequence 
(Jinek et al. 2012). Different Cas9 may have different PAM sequences (Mojica et al. 2009). 
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The Cas9 protein from Streptococcus pyogenes (SpCas9) requires 5'-NGG-3' PAM sequence 
(Jinek et al. 2012). To make the three-component CRISPR-Cas9 system easier to use, an 
artificial linker sequence is introduce to fuse crRNA and tracrRNA into a single chimeric 
guide RNA (sgRNA) that mimics the natural crRNA-tracrRNA hybrid RNA (Jinek et al. 
2012). In this tow-component system, the SpCas9 protein along with the sgRNA could be 
programmed to cleave any sequence preceding a 5'-NGG-3' PAM sequence in mammalian 
cells, including sequence after 5’-CCN-3’ on the complementary strand (if you using only 
one strand information). Across the whole human genome, there are about 190,000 specific 
gRNA-targetable sequences, and around 40.5% exons of genes can be targeted with SpCas9 
(Mali et al. 2013).  
5.4 CRISPR SCREEN 
In the history of biology, genome-wide loss-of-function screenings have provided a 
wealth of information in diverse cell model, human cells, Drosophila cells, and mouse cells 
(Berns et al. 2004; Boutros et al. 2004; Carette et al. 2009; Jiang et al. 2009; Rad et al. 2010). 
Recent advances in CRISPR-Cas9 genome editing technology makes genome-wide loss-of-
function screens in human cells possible. 
Large-scale genetic screen was previously dominated by RNA interference (RNAi), but 
recently CRISPR-Cas9 technology has make its way into the field of genetic screen (Shalem 
et al. 2014; Wang et al. 2014b; Zhou et al. 2014). CRISPR screen usually contains five steps. 
1) Design sgRNAs libraries at large scale according the demand of the applications. 2) 
Generate a pool of sgRNA-expressing lentivirus or other genome integration constructs by 
array synthesis and library cloning. 3) Generate mutant cell libraries by transfect or transfer 
these sgRNA-expressing libraries into the cells of interest. 4) Apply positive or negative 
selections to the mutant library, such as FACS for markers, and drug resistance. 5) Back-
tracking the mutations by reading the sgRNAs sequence integrated in the genome, usually 
with deep-sequencing. The cells with selected mutations will enrich in the destined 
population thus the sgRNAs carried by the cells will ranks on the top comparing the other by-
chance sgRNAs in the population. The genes targeted by the top-ranked sgRNAs are the hits 
for the screen. 
Compared to traditional genetic screen with RNAi, there are several improvements with 
CRISPR-Cas9 technology. First, CRISPR-Cas9 inactivates genes at the DNA level, while 
RNAi acts on the mRNA, which might result in incompleteness of protein depletion. Second, 
CRISPR-Cas9 should enable the screens for non-transcribed or regulatory elements, such as 
promoters, enhancers, silencers, as well as the intergenic regions, which are normally 
inaccessible by means of RNAi. Third, mutations caused by the CRISPR-Cas9 are some 
permanent scars fixed in the genome independent of the state of the cells, while the effects of 
RNAi are undetectable when the gene complete its mission and stop transcribed. Therefore, 
with CRISPR-Cas9 technology, it is possible to verify mutations at endpoint of a transition 
process, such as differentiation, while RNAi effect is difficult to verified at the end point or 
the beginning. However, there are also some limitations with CRISPR-Cas9 technology, such 
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as the off-target problem, the different efficiency of knocking out genes. But overall, CRISPR 
screen is a powerful tool for genome-wild functional genetic interrogation. 
The primary assay is the key for a screen. Since the publication of CRISPR screen, 
numbers of assays have been used in such screens. Survival assay is the simplest, but 
strictest, assay for CRISPR screen. There are lots of such studies. Shalem et al screened for 
genes whose loss in involved in resistance to vemurafenib (a therapeutic RAF inhibitor) in 
melanoma (Shalem et al. 2014). Wang et al screened for resistance to the nucleotide analog 6-
thioguanine (6-TG) identified all expected members of the DNA mismatch repair (MMR) 
pathway (Wang et al. 2014b). Ma et al identified genes essential for West-Nile-Virus-induced 
cell death (Ma et al. 2015). Birsoy et al Identifies metabolic genes whose loss sensitizes 
human jurkat cells to phenformin (a mitochondrial complex I inhibitor) (Birsoy et al. 2015). 
CRISPR screens can also be used in identifying genes for signaling transduction (Parnas et al. 
2015; DeJesus et al. 2016; Wang et al. 2017; Pusapati et al. 2018), tumor metastasis (Chen et 
al. 2015), drug resistant in primary tumor cells (Ruiz et al. 2016), muscle formation (Bi et al. 
2017) and cellular metabolism (Arroyo et al. 2016).   
Approaching to the cardiogenesis problem, genome-wide screen is an unmet needed. For 
large-scale screens, in-vitro cardiac differentiation is currently the best choice. For any 
screens, variable control plays a central role during the process. Influence from external 
factors should be reduced to the minimal. Compared to in-vivo system, the in-vitro system 
has much less uncontrollable factors and gives the most lucid readout. Cardiac differentiation 
from hPSCs closely mimics cardiac development in the embryo and is the ideal model for 
cardiogenesis in vitro (Laflamme and Murry 2011). With hPSCs cardiac differentiation 
models, not only can we verify the established cardiac disease model, but also genetically 
explore new processes of cardiogenesis. CRISPR-Cas9 loss-of-function screen technology 
together with the robust, high efficient GiWi cardiac differentiation protocol make it feasible 
to carry out genome-wide genetic screen for the important genes for cardiogenesis. 
Differentiation of hPSCs into the cardiovascular lineages is a multi-step process that involves 
initial epithelial to mesenchyme transition, mesoderm induction and specification, cardiac 
specification and differentiation, and functional maturation (Laflamme and Murry 2011). 
Each intermediate cell can be characterized by the expression of different markers, although 
the lineage marker tree is in its preliminary state.  
In contrast to RNA-seq profiling method which gives a genome-wild expression profile 
of the specific intermediate cell types, CRISPR screen is aim to discover genes that 
contributes to the formation of the specific intermediate cell type or directs the fate decision 
of the progenitors. CRISPR screen is more based on the gene function, making use of the 
cause-and-effect relationship between the genes and direct by the function of the genes. 
CRISPR-Cas9 genome-wide screen would be able to provided more wealthy information 
than just RNA-seq described profiling. 
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6 AIMS 
In order to provide the molecular and cellular mechanism of human cardiogenesis and 
congenital heart disease, we aim to generate progenitors from hPSCs that can self-assemble 
into the ventricular muscle tissue and to identify essential genes that control the formation of 
such progenitors. 
Paper I – Aim 1: to generate human ventricular progenitors that can produce the 
ventricular muscle tissue in vivo. Aim 2: to functionally and molecularly characterized these 
progenitors. Aim 3: explore the therapeutic potential of these progenitors.  
Paper II – Aim 1: to establish CRISPR-Cas9 as a tool for investigating cell fate decision 
in hPSCs. Aim 2: to investigate the roles of β-catenin in early cell fate decision of hPSCs. 
Paper III – Aim 1: to examine the role of SMAD4 in human cardiomyocyte 
differentiation. Aim 2: to identify the earlies signaling pathways in TGFβ	superfamily	and 
their essential roles in human cardiogenesis.  
Paper IV – Aim 1: to develop genome-wide CRISPR screen for human heart progenitor 
formation. Aim 2: To investigate role of the identified candidate gene in cell fate decision of 
early precursor cells. 
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7 RESULT SUMMARY 
7.1 PAPER I: HVP 
Human ISL1+ Ventricular Progenitors Self-Assemble into an In Vivo Functional Heart 
Patch and Preserve Cardiac Function after Infarction 
The generation of human ventricular tissue from human pluripotent stem cells not only 
holds great promise to regenerate a failing heart, but also will serve as valuable model for 
studying human cardiogenesis. In-vivo tissue formation requires a niche that allows the cells 
to trigger the machinery that produce vascularization and matrix formation cues. Therefore, 
additional components are usually required, such as synthetic matrices, scaffolds and vascular 
lineage cells. Moreover, these components, together with the cells, are demanded to assembly 
themselves correctly into a functional cardiac muscle tissue. In paper I, we applied 
developmental principles using ventricular progenitors instead of beating cardiomyocytes to 
generate in-vivo human ventricular muscle patch without the assistant of additional matrices 
and scaffolds.  
By using more potent inhibitors of GSK3 and PORCN, we optimized an existing two-
step protocol to efficient generation of human ventricular progenitor (HVP) over 6 days. And 
the stage conversion from pluripotent stem cells to ISL1+ HVPs and subsequent in-vitro 
differentiation were extensively characterized by immunostaining and RNA-sequencing. 
These analyses demonstrated the distinct markers for each stage: pluripotency stage, 
POU5F1, NANOG, and SOX2; primitive streak or early mesoderm stage, TBXT, EOMES and 
MIXL1; cardiac mesoderm stage, MESP1, KDR, PDGFRA; cardiac progenitor or early 
cardiomyocyte stage, ISL1, NKX2-5, MEF2C; and cardiomyocyte stage, TNNT2, MYH7, 
PLN, RYR2, MYL7, MYL2. By examining the marker expression, we also define the 
corresponding time points during the differentiation for these stages. The early mesoderm 
stage happens on day 1, and quickly transitive to cardiac mesoderm on day 2-3. The cardiac 
mesoderm cells enter the cardiac progenitor stage on day 5-7. The beating cardiomyocytes 
can be observed usually on day 7-8 or slight later day 9-10. With these results, we focus on 
the day 6 progenitor cells, to study and character their properties. 
In order to further purified cardiac progenitors from the day 6 cells, surface markers are 
needed. By analyzing the gene expression patterns in the RNA-Seq dataset, we applied 4 
criteria to select candidate marker genes: (1) high day 6 to day 0 ratio; (2) correlation with 
ISL1 expression pattern; (3) cell surface proteins; and (4) highly expressed at day 6.  Five 
candidates fulfill all the criteria: JAG1, FZD4, FGFR3, LIFR, and TNFSF9. Further live-cell 
flow cytometry analysis identifies, in these 5 candidates, LIFR is the best surface protein 
mark for cardiac progenitor on day 6. The LIFR marks more than 87.4% of the cell 
population on day 6. 
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Next, we characterized the lineage potency of these day 6 cardiac progenitors and the 
electrophysiology (EP) properties of the cardiomyocytes derived from them. In the clonal 
assay, day 6 cells were re-plated and after 3 weeks of differentiation, the cells became 
cTnI+SMA+, which indicates immature cardiomyocytes, but no VE-cadherin (CD144, 
CDH5) positive endothelial cells. And on differentiation day 15 and onwards, the majority of 
the cells were positive for ventricular marker MLC2v (MYL2), cTnT(TNNT2), and NKX2-5, 
but negative for MLC2a (MYL7), and HCN4. These results demonstrated these day 6 cardiac 
progenitors are ventricular muscle progenitors, hence named human ventricular progenitors 
(HVPs). To further characterized the maturation potential of HVPs, we performed patch 
clamping, optical mapping and calcium imaging of the cardiomyocytes derived from HVPs. 
Via patch clamp, we showed over 90% of the NKX2-5+ cells had a polarized diastolic 
membrane potentials and a ventricular-like action potential. And by using optical mapping 
and calcium imaging, we demonstrated the propagation of both action potential and calcium 
transient in-vitro. This result indicates the network activity and electrical coupling.  
By examining the parameters from the EP-studies, there are a couple of EP-parameters 
indicated the cardiomyocyte derived from HVP are mature. Firstly, the APD90/APD50 ratio 
is small than 1.2, which recapitulates the AP configuration of native adult human ventricular 
myocytes. Secondly, comparing with the cardiomyocytes derived from a EB-based protocol 
and HVPs, the funny current is reduced by half. These features suggestion the maturation of 
the HVP-derived cardiomyocytes. 
To analysis HVPs in-vivo, we transplanted the HVPs under the renal capsule in a highly 
vascularized site. The choice of renal capsule is based on these advantages:1) it is separated 
from other organs. The transplanted cells would be contained within the capsule. 2) the 
capsule is highly vascularized, it is easier for the transplanted cells to survive. 3) the 
retroperitoneal location of the kidney is easy accessed for both the surgery and imaging. In 
order to further purify the day 6 cells, we negatively sorted out the cells expressing TRA-1-60 
(PODXL), a pluripotent stem cell surface marker. Three million TRA-1-60 negative day 6 
cells, mainly HVPs, were transplanted under the kidney capsule of immunocompromised 
NOD scid gamma (NSG) mice (n =30). A patch of xeno tissue was engrafted on the surface 
of the murine kidney after 2 months. The graft resembled a human ventricular muscle wall, as 
the immunostaining reveals the graft consisted cTnT and MLC2v positive ventricular 
myocytes. Furthermore, electron microscopy (EM) showed aligned sarcomeres, with distinct 
A-band, I-band, M-line and Z-line. The desmosomes were also presence in the EM image of 
the graft. 
To assay the engraftment of these cells, the physical size is measured, which is about .6 
cm in length and .2 cm in thickness. More importantly, the graft was vascularized by the host 
circulation network, as red-lectin, which is injected through the tail of the host, can be found 
in the graft’s vessel. The graft also produced its own extracellular matrix, containing human 
fibronectin and laminin. In addition, the beating graft can be detected by ultrasound imaging 
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in vivo. Taken together, the results demonstrated a fully function ventricular muscle tissue is 
assembled through a cell-autonomous pathway of the HVPs. 
Engraftment would require the cells to commit the ventricular myocyte fate and create 
necessary cues for assembly, and proliferate for scaling-up after the transplantation. If the 
cells were transplanted at earlier stage, such as day 3, MESP1+ cardiac mesoderm cells, the 
cells might become other cell types other than ventricular myocytes, which might overwhelm 
the tissue and turn into tumor-ish graft. When transplanted cells at later stage, such as day 10, 
NKX2-5+ beating cardiomyocytes, the cells had very limited proliferation capacity and lose 
the capacity to interface with other tissue to build a necessary niche for the formation of the 
muscle tissue. The day 3 and 10 cells transplantation experiment demonstrated the unique 
engraftment property of the HVPs, and a developmental time window for tissue formation. 
To further explore the therapeutic potential of the HVPs, we transplanted the HVPs into 
the hearts of NSG mice, with and without myocardial infarction (MI). Ventricular myocytes 
can be found in the heart without MI in both short term (2 months) and long term (8 months). 
The ventricular graft patch was vascularized and integrated with the host myocardium via 
connexin 43. In the MI hearts, at the 2-month time point, MRI revealed improved ejection 
fraction, augmented wall thickening, and improved contractility. 
In summary, these results demonstrate the HVPs generated from hPSC reassemble the 
ventricular myogenic progenitors that builds the ventricular muscle tissue during human 
cardiogenesis. It will be of interest to study the genetic control of these cells, such as their 
formation, proliferation, and differentiation. In the next phase of the study, we try to identify 
the essential genes for the formation of HVPs, from the absolute basic to unbiased genome-
wide screen.   
7.2 PAPER II: Β-CATENIN  
Interrogating Canonical Wnt Signaling Pathway in Human Pluripotent Stem Cell Fate 
Decisions Using CRISPR-Cas9 
Canonical Wnt/β-catenin signaling pathway is one of the most important signaling 
pathways in developmental biology. And β-catenin sits in the center of this pathway.  In the 
absent of Wnt, a destruction complex consisting AXIN, APC, and GSK3 binds to and 
phosphorylate and degraded then β-catenin, preventing the accumulation of β-catenin in the 
nucleus. When Wnt binds to the Frizzled receptors, the signaling cascade inhibits the 
destruction complex, allowing the β-catenin gets inside the nucleus and activate targeted 
genes.  
The Wnt signaling has been documented of importance for both the self-renewal and 
differentiation of hPSCs. The role of Wnt signaling in the hPSC self-renewal is controversial. 
Mouse embryonic stem cells (mESCs) are common cultured in medium contains GSK3β & 
Mek1/2 inhibitors, sometimes, but not required to include leukemia inhibitory factor (LIF) 
(Ying et al. 2008). This demonstrated the self-renewal of ES can be driven by Wnt signaling. 
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Similar results for human ES were observed in early culture conditions (Sato et al. 2004). On 
the other hand, β-catenin knock down experiments showed the Wnt signaling is not essential 
for the self-renewal of hPSCs (Davidson et al. 2012; Lian et al. 2012). Therefore, the 
essential role of β-catenin in the self-renewal of hPSCs is yet to be determined. 
In the GiWi cardiomyocyte differentiation protocol, GSK3 inhibitor were used to inhibit 
the destruction complex and activate the Wnt targeted genes. However, the GSK3 has nearly 
100 proteins proposed to be its substrates, including c-MYC, HIF-1a and β-catenin. The 
inhibition of GSK3 might have a broader impact on the cells than merely Wnt activation. To 
find out the essential role of β-catenin in human cardiac differentiation, direct genetic 
evidence is required.  
In this study, we used CRISPR-Cas9 system to generate β-catenin mutated hPSC lines 
and further utilized these cell lines to study the role of canonical Wnt signaling in hPSC self-
renewal and differentiation. We used an engineered nuclease Cas9-GFP and an sgRNA 
targeting exon 5 of CTNNB1 to mutate β-catenin. We chose one of the β-catenin negative 
clones for further study. By sequencing the targeted region, we found the first allele had 8bp 
deletion and the second allele had more than 100bp deletion. This compound heterozygous 
clone can be expanded for long-term without differentiation in E8 medium and express 
pluripotency marker Oct4. The success of generating β-catenin mutated hPSC clone 
demonstrates β-catenin is not required for hPSC maintenance. 
Next, we moved on the question that whether β-catenin is required cardiomyocyte 
differentiation. We induced hPSC differentiation with 6µM CHIR for 24 hours. The 
mesendoderm marker brachyury (T or TBXT) was strongly expressed in the wild types, 
while it was undetectable in the mutants. This result demonstrated the CHIR induced 
mesendoderm differentiation is triggered through β-catenin dependent pathways and the 
requirement of β-catenin for initiating the mesendoderm differentiation. By using GiWi 
cardiomyocyte differentiation protocol, the wild type hPSCs yielded more than 90% cTnT+ 
cells by day 15, while no cTnT+ cells were detected from the mutant hPSCs. 
With CRISPR-Cas9 genome editing technology, we provide the first genetic evidence 
that β-catenin is essential for the mesendoderm formation and subsequence cardiomyocyte 
differentiation, but is dispensable for human pluripotent stem self-renewal. 
7.3 PAPER III: SMAD4  
SMAD4 is Essential for Human Cardiac Mesodermal Precursor Cell Formation 
Using CIRSPR-Cas9 to target CTNNB1 clarifies the chemical stimulation in the GiWi 
protocol is indeed through β-catenin. But it wouldn’t allow us to see downstream of the chain 
reaction caused by β-catenin and its targets. TGF-β superfamily signaling pathways, 
including BMPs, Activin, and Nodal, have been used in growth factor based cardiomyocyte 
differentiation. In small molecular based differentiation protocol, such as GiWi, these 
pathways have been left untouched. Pharmacology studies have been showed that these 
  35 
pathways are required for the differentiation (Lian et al. 2012; Burridge et al. 2014). 
However, the complex interactions between the WNT/ β-catenin and the TGF-β superfamily 
signaling pathways make these studies a bit difficult to interpret in the contest. A genetic 
study would clarify the essential role of the TGF-β superfamily signaling pathways in cardiac 
differentiation.  
There are more than 30 ligands, 4 type-II and 7 type-I receptors in TGF-β superfamily 
signaling pathways. The complexity of singling pathways required a better way to target 
them. The Ligands of the TGF-β superfamily binds to their receptors and caused the 
phosphorylation of the R-Smads (SMAD1/5/8 and SMAD2/3). The phosphorylated R-
SMAD(s) then binds the common SMAD, SMAD4, and transported into the nucleus to active 
or suppress the targeted genes. Therefore, by targeting SMAD4, the whole signaling pathway 
family would be impaired.  
When targeting a gene, especially the ones expressed in hPSCs, is hard to predict 
whether or not it will affect the self-renewal and pluripotency of the hPSCs. The status of the 
hPSCs must be checked first. In our cases, the hPSCs were cultured in E8 medium, which 
contains TGF-β1 as one of the essential components. And numbers of studies have suggested 
that Nodal signaling pathway can enhance the expression of NANOG, which supports the 
pluripotency of the hPSCs. However, there is a study showed that the knockdown of SMAD4 
in hESCs would not induce rapid differentiation, just has some trouble in long term culture 
(Avery et al. 2010). Thus, whether SMAD4 is essential for the self-renewal and pluripotency 
remains a question.   
In this study, we used PiggyBac CRISPR-Cas9 system to generate SMAD4 mutated 
hPSC lines. The successful of generating single-cell derived cell lines demonstrated the 
SMAD4 is not required for the self-renewal of hPSCs. By immunostaining, we demonstrated 
these SMAD4 mutated cell lines express pluripotency marker POU5F1, NANOG, SOX2. 
Furthermore, RNA-Seq analysis revealed these pluripotency markers were not differentially 
expressed between the wild type and mutant hPSCs, while the TGF-β signaling and target 
genes including LEFTY1, LEFTY2 and CER1 were down regulated in mutant hPSCs. Taken 
together, we demonstrated that SMAD4 is not required for hPSC self-renewal. 
Since the SMAD4 mutated hPSCs maintains their pluripotent identify, we next test 
whether SMAD4 is essential for cardiomyocyte differentiation. We differentiated the wild 
type and mutant hPSCs, using both the small molecule based and growth factor based 
differentiation methods. In both cases, the SMAD4 mutants yield zero detectable TNNT2+ 
cardiomyocytes, while the wild type cells yielded more than 80% of cardiomyocyte with 
GiWi method, and 40% with Activin A/BMP4 method. We further re-expressed SMAD4 in 
the mutant cells, and these cells restored their cardiomyocyte differentiation capacity. These 
results suggest SMAD4 is absolutely essential for cardiomyocyte differentiation.  
To find out how the SMAD4 mutant hPSCs fail to generate cardiomyocytes, we 
performed transcriptome profiling at different stages during the differentiation: day 0 
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pluripotent stem cells stage, day 1 primitive streak and early mesoderm stages, day 3 cardiac 
mesoderm stage, and day 6 progenitor and early cardiomyocyte stages. From the 
transcriptome profile, we found that the major difference begins at the cardiac mesoderm, 
suggesting the failure of generating cardiac mesodermal precursor cells. And further 
immunostaining showed MESP1+ cardiac mesoderm precursors were missing from the day 3 
mutant cells. And we further examined the ligands of TGFβ superfamily. It turned out that 
NODAL was the only active signal in the TGFβ superfamily, instead of Activin A or BMPs, 
which we used to induce cardiomyocytes differentiation. On the other hand, from the 
developmental view, NODAL and WNT are the major signals that establish the axis of 
embryos (Tam and Loebel 2007; Arnold and Robertson 2009). By detail analysis, the 
differential expression of the wild type and mutant cells on day 1, we found the expression of 
primitive streak genes were present but much weaker than the wild type cells, while the 
expression of pro-neuroectoderm genes were higher in the mutants.  
Taken together, these results suggested the distinct the role of the WNT/β-catenin 
signaling and the NODAL/SMAD4 signaling in the earliest step of human cardiogenesis. The 
WNT/β-catenin signaling can active the cardiogenesis relative genes, which largely in the 
primitive streak (PS) genes set, and this process can happen in both wild type and the 
mutants. The activation process is independent of NODAL/SMAD4 signaling. However, the 
role NODAL/SMAD4 signaling play in the process is to enhance the expression of the PS 
genes to the level that allowing the formation of mesendoderm lineage, otherwise the cells, 
even with the activated PS genes, would fall back the default neuroectoderm fate. 
7.4 PAPER IV: SCREEN-ZIC2 
Genome-Wide CRISPR Screen Identifies ZIC2 As an Essential Gene That Controls the 
Fate of Mesodermal Precursors to Human Heart Progenitors 
After validating the β-catenin and SMAD4 as two of the essential genes for the 
formation of human heart progenitors, we sought out to development a new technology to 
unbiasedly screen for the essential genes across the whole genome.  In this study, we 
developed a two-stage genome-wide CRISPR screen using hPSC system.  
First, we created three hPSC libraries carrying gene mutations covering more than 6000 
genes. Then, we combined these three libraries to ensure the diversity of the libraries and 
differentiate the libraries into cardiac progenitors. By monitoring two key cardiac markers: 
MESP1 and ISL1, we were able to assay the formation of cardiac mesodermal precursors and 
cardiac progenitors respectively. Cells with essential gene mutated would fail to express these 
markers and enrich in the MESP1 or ISL1 negative population. Therefore, by comparing the 
sgRNA enrichment in the marker negative and positive population, we can identify the 
corresponding gene as the potential candidates.  
From the screen output, we compiled a list of 15 candidate genes. After validating 7 of 
these, we identified ZIC2 as a new essential gene for cardiac progenitor formation. All three 
ZIC2 mutated hPSC lines produced less than 10% of cardiomyocytes. Via immunostaining, 
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we found the ZIC2 mutated cells failed to express MESP1 at the cardiac mesoderm formation 
stage. And surprisingly, the ZIC2 mutated cells also express ISL1 on day 6, but there were 
few cardiomyocytes produced in the end. These results suggest ISL1 can be active by a 
MESP1 independent pathway, but the myogenic ISL1 progenitors are from the MESP1 
lineage.  
To further study the essential role of ZIC2 in human cardiogenesis, we used RNA-Seq to 
compare the transcriptome difference at different stages: day 0, the epiblast stage, day 1, 
primitive streak, day 2, early mesoderm, day 3, cardiac mesoderm and day 6 cardiac 
progenitor. The mutant and wild cells follow a similar differentiation trajectory, with further 
apart at the later stage. And the differential expression (DE) analysis reveals the DE genes are 
increasing from 50 on day 1, to 293 on day 6. By using the classical cardiac differentiation 
marker genes, we found the mutant cells were able to become mesoderm precursors, but 
failed to turn into cardiac progenitors. And the up-regulated genes in the mutant cells formed 
a network regulating the skeleton development. Among these up-regulated genes, there are a 
number of osteoblast marker genes, such as RUNX2, DCN, and OGN, while the cardiac 
genes, such as NKX2-5, MEF2C, PLN, and MYH6, were down-regulated. These results 
suggest the essential role of ZIC2 in hPSC cardiac differentiation is to regulate the cell fate 
decision of mesodermal precursor to cardiac progenitor. Under the GiWi differentiation 
condition, the ZIC2 mutated hPSCs switch to osteoblast fate from the cardiac progenitor fate.  
Two functions of ZIC2 have been reported. First, ZIC2 can bind directly to TCF4 and 
inhibit the transcriptional activity of the β-catenin/TCF4 complex (Pourebrahim et al. 2011). 
Second, ZIC2 can also function with Mbd3/NuRD in regulating the chromatin state and 
transcriptional output of genes linked to differentiation (Luo et al. 2015). Based on these 
previous studies, the mechanisms we proposed here is the inhibitory function of ZIC2, which 
allows the more specific differentiation molecular program correctly happen. During 
gastrulation, cells were migrating through the primitive streak and forms all types of 
mesodermal precursor cells. The activation signal is overwhelming. Without a strong 
inhibitory system, different differentiation processes were all activated and compete to take 
control of the cells. The inhibitory system can dampen lots of spiking signaling and allowing 
the primary signals to convert the cells into right progenitors. 
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8 DISCUSSION 
8.1 THE UNIQUE ENGRAFTMENT PROPERTY OF HVP 
Besides the committing to ventricular myocyte fate, engraftment is one of the distinct 
features the HVPs. As mention previous, engraftment is a complicate process, involving cell 
survival, migration, proliferation, differentiation, maturation, integration, electrical coupling, 
and vascularization. The HVPs resemble the in-vivo ventricular myocyte wall builder. Their 
genetically build-in program can accomplish lots of these engraftment tasks naturally, such as 
proliferation, differentiation, matrix formation, vessel recruitment, and self-assembly. The 
proliferation capacity of HVPs enables the cells to expand and differentiate from a few 
million HVPs to, perhaps, a billion of ventricular myocytes. The strong bias towards 
ventricular myocyte in differentiation generates specifically ventricular muscular tissue 
instead of a mixture of other types cardiomyocytes. The self-secreting matrix protein provides 
the mechanism support and signaling niche for the maturation and integration of the 
ventricular myocytes. And the recruitment of host vessel allows the tissue to survive and 
expand into a 3D functional, force-generation ventricular myocyte tissue. And the kidney 
capsule HVP transplantation clearly demonstrated a cell-autonomous pathway, through 
which the HVPs can generate a 3D vascularized, functional ventricular wall without the 
assistant of external cues.  
This unique engraftment property of HVPs resides in the cell autonomous pathway that 
empower them. With RNA-Seq data, we have the transcriptome profile of the HVPs, which 
offers the chance to identify the molecular modules for this engraftment pathway, such as the 
cell fate restriction, matrix secretion, and vessel recruitment. By comparing the profiles of the 
engraftable and un-engraftable cell, the modules should stand out for themselves. And the 
time window, we have defined in the HVP paper, have provide a comparison guide line. 
However, due to the dramatically change of cell identify, lots of genes were differentially 
expressed. As all these molecular modules pool together, all we can conclude is that the 
progenitor genes are important the engraftment. Though a few interesting genes are turn up, 
such as, LIFR, FZD4, LAMMA1, VEGFA, further studies are required to investigate their 
roles in engraftment. Meanwhile, the surface markers we identified according to their 
expression patterns, have the potential to further enrich HVPs from the day 6 cell population, 
which might improve the engraftment. 
Other aspects of engraftment, such as mechanical and electrical integration, might not be 
a build property of HVP. For that, other interventions should be employed. These challenges 
are the obstacles have to be overcome, before the use of HVP for regenerating the heart. By 
studying the details molecular pathways of the HVPs, we should one day be able to pre-
program these HVPs to taken on new property, like resolving scar tissue, turning fully 
mature.  
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8.2 A PEEK INTO THE MOLECULAR COMPLEXITY OF CARDIOGENESIS 
For a decade and half, efforts have been focus on improving the cardiomyocyte 
differentiation protocols, not so much on the molecular mechanism how the cells become 
cardiomyocytes. Since the development of robust differentiation protocols, the mechanistic 
studies of the differentiation program have become more of interest. One of such example is 
Rao et al. 2016. In Rao’s study, EOMES is proposed to be the driving force to suppress 
SOX2, which intends to direct the hPSC towards neuronal fate and later study (Pfeiffer et al. 
2018) showed by controlling the expression of EOMES can indeed induce cardiac 
differentiation.  
In our first study, the HVP project, we have documented a detail transcriptome profiles 
of the differentiation process. There are around 4K genes, 20% of the protein coding genes, 
are differentially expressed during the whole cardiac differentiation process. Most genes 
required for initiating the differentiation program were activated at very early stage. Lots of 
genes were turned on in day 2 samples. Another thing we learn from the expression pattern is 
that not only the activation is important, the gene inactivation play equally important roles, as 
lots of genes were shut down on day 4 and 6. Another interesting in the profiles are the 
distinct stages can be obtain automatically via clustering the expression, and these distinct 
stages corresponding to the developmental stages. These genome-wide description gives a 
very rough picture how the program is executed, and similar dataset can also be found in 
other studies (Piccini et al. 2016; Tompkins et al. 2016).  
The cardiac lineage arises from the cardiac mesoderm and the cardiac mesoderm comes 
from the mesoderm cells migrated though the primitive streak. However, the diversity of the 
mesoderm cells paints a complicate developmental landscape (Loh et al. 2016). These cells 
can give rise to multiple lineages, including, paraxial mesoderm and lateral mesoderm. 
Subsequently, the paraxial mesoderm give rise to early somite and then differentiated into 
dermomyotome and sclerotome et al. And the lateral mesoderm can become cardiac 
mesoderm and limb bud mesoderm. Therefore, the mesoderm cells have lots of different cell 
fate choices, and their decisions are the combination of the signaling cue from the 
surrounding and the genetic programs build-in these cells. By varying the signaling cues, the 
mesoderm cells can be directed to a given lineage. On the other side of the question, given an 
optimized signaling cue, what is the genetic program that locks the fate of these mesodermal 
cells is equally interesting.  
To define this genetic program, the first step is to identify the essential component in this 
program. In the β-catenin study, we showed β-catenin is the key switch for initializing the 
differentiation program. Upon stimulation, the CTNNB1 mutant cells didn’t express even the 
first stage, primitive streak (PS) stage, maker TBXT. And these mutants didn’t produce any 
cardiomyocyte in the end. In the SMAD4 mutants, primitive streak stage can be reached. PS 
markers, such as TBXT, MIXL1, EOMES, did expressed in the day 1 SMAD4 mutant cells, but 
just not as high as the wild type cells. And previous study show β-catenin can activate both 
primitive streak and neural crest genes (Funa et al. 2015) during the GSK3 inhibition in 
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hPSCs. And our RNA-Seq result had similar result in the mutant cells, but not in the wild 
type cells. This suggests the β-catenin is able to trigger the expression of the PS genes, and is 
independent of NODAL/SMAD4, but the NODAL/SMAD4 pathway can enhance the 
expression of PS genes. Without this enhancement, the cell just cannot enter the next phase of 
differentiation, namely cardiac mesoderm formation, and eventually drop back to the 
neuroectoderm fate. In the ZIC2 study, with both WNT/β-catenin and NODAL/SMAD4 
signaling pathways intact, the ZIC2 mutant cells were able to enter the mesoderm cells, but 
most of them fail to commit the cardiac lineage. Unlike β-catenin and SMAD4, ZIC2 is not 
known to link to a specific signaling pathway. Two studies reported ZIC2 interacts with β-
catenin/TCF4 and Mbd3/NuRD. Both interactions attenuate the transcriptional activity. And 
our RNA-Seq data supports this notion, as there are more active gene in the ZIC2 mutant cells 
comparing to the wild type cells. We hypothesis that ZIC2 functions as a key component of a 
gene suppressor complex, attenuating the transcriptional activity after the β-catenin activation 
and NODAL/SMAD4 enhancement. Most of the ZIC2 mutant cells were misled by other 
signaling into another mesodermal fate, such as osteoblast. Taken together, the basic 
molecular picture of the cardiac differentiation is: 1) β-catenin enters the nuclear and 
activates both PS and neuroectoderm genes, including NODAL. 2) the NODAL/SMAD4 
cascade, allows the SMAD complex translocate into the nuclear and enhance the PS gene and 
direct the cells at PS stage to the mesoderm fate. 3) the ZIC2 repressor complex attenuate the 
transcription activity after the mesoderm precursors are formed, leaving the cell fate decision 
to the external signaling cues. 
In hPSC cardiomyocyte differentiation, the first stage stimulation plays a crucial role. 
The strength and duration of stimulation often determines the efficient of the differentiation. 
Our studies have provided some information about the genetic program of this crucial step. 
This step is corresponding to the gastrulation and mesoderm formation steps in-vivo, when 
the mesodermal precursor begins for emerge. Some of these mesodermal precursors later 
commit to cardiac mesoderm, which give rise cardiac progenitors. To form a healthy heart, 
these progenitors are demanded to correctly completely complicate tasks, such as the 
migration, proliferation, differentiation, and assembly et al. Mistakes in these progenitors are 
the potential causes of many congenital heart diseases.  
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9 CONCLUSION 
More and more advance techniques have been adapted to study congenital heart disease. 
Our knowledge about human genome is growing faster than ever before. More information 
from congenital heart disease will soon be available in the databases. In the research field, the 
framework we choose to integrate these clinical results would be the key to advance the 
whole field. The progenitor theory framework operates above the molecular interaction at the 
cellular level, focusing on the cells instead individual gene. However, the difficulty is how we 
identify the progenitors.  Single gene marker is not always faithful. Through evolution, many 
key genes have been used and re-used multiple times, therefore a unique marker gene rarely 
exists. Single-cell biology provides whole-genome profile, but it is always difficult to used 
comparing to a marker gene. To get a clear picture of the cardiac progenitors, a better 
approach is needed to define and assay these heart-builders. 
CHD, mice, hPSCs, three models, each has its own advantages and limitations. 
Observations from the clinical are valuable but we can do only little more than just keeping 
records, which limits our options in testing hypothesis. The mice model provides us great 
insights. However, the difference between mice and human mean that some process in human 
can never be observed in mice. The hPSC model is an in-vitro system. We are unsure the 
faithfulness of the system and how human cardiogenesis really happen in vivo. A new 
cardiogenesis system is needed to propel the next break-through in human cardiogenesis. The 
HVP project has put forward a new organ-on-organ system to study the human ventricular 
muscle tissue formation, at both cellular and molecular level. Powerful genome editing tools 
allows us to directly interrogate the critical role the gene plays in the progenitor. Our study 
has advanced the use of hPSC model to understanding the process of cardiogenesis in human. 
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